Foreword — Why AM I Writing This

I did not come to TechBio as a distant observer but grew into it. When I was studying life sciences engineering, the early signs of “software eating bio” were just starting to appear. Computational tools were making dents in how biology was done, and for me it was impossible not to be fascinated.

Fast forward a few years, and I am now operator inside a TechBio startup (shameless plug) leading AI development. That vantage point is really a strange mix. Some days I get swept up in the hype, convinced the next model drop is going to change everything; other days, the scientist in me wants to push back, to ask for proof, for data, for translation into the clinic. Balancing those two minds: both the early adopter and the skeptic is hard.

But it’s also what makes TechBio such a fascinating space to build in.

And then there’s Africa.

Coming from the diaspora, I studied and trained abroad, where most of the breakthroughs and AI-driven advances in drug discovery were happening in the West.

But I kept asking myself: what about here? What about my continent?

At first, it felt like we were always on the receiving end of innovations born elsewhere. But as I dug deeper, I realized something the very bottlenecks I was seeing firsthand inside TechBio like the gaps in translation, the missing data closer to humans, well that is were exactly where Africa holds an unfair advantage.

That’s what this deep dive is about. Not a hype piece, not a catalog of every new startup, but an attempt to map the playbook, show where TechBio has already delivered, and point to the next frontier

→ one that may well be written in Africa.

If you’re an investor, I want you to come away with clarity on what makes a TechBio defensible, where the real opportunities lie, and why the continent is positioned for outsized returns.

If you’re a scientist, founder, or operator, you’ll find the logic of the playbook, examples of what works (and what doesn’t), and maybe a spark for your own next venture.

The full story starts just ahead. But first, let’s look at the latest wave, AI agents and what they tell us about how fast new technology moves from silicon into cells.

TL;DR

• TechBio has gone from hype to playbook: data → platform → assets.
• The next bottleneck is translation: generating data closer to humans.
• Africa holds the unfair advantage to solve this, thanks to its diversity, newly acquired infrastructure, and emerging research ecosystem.
• Companies are already being built on this frontier, clear venture opportunities exist, exemples of exits and more investors should catch up.

Not TechBio Yet But Another Reminder Pharma Can’t Escape the Tech Cycle

I f you want to know where the next disruption in pharma will show up, follow the broader tech cycle. Every new wave of technology now leaves its mark on the industry. In the age of Tech x Bio, there’s nonstop traffic between silicon and cells: cloud, machine learning, robotics and now, AI Agents.

I see this almost daily. My feed is flooded whenever a new model drops or a product launches. At first it feels like a headline meant only for the tech crowd. But give it a few months, and suddenly that “just another AI update” is wired into pharma workflows with Paul Hudson, CEO of Sanofi, giving full interview to McKinsey on how transformative it is for the industry. One thing is clear: whether in discovery, trials, or manufacturing, the two domains have become inseparable.

YC’s (famous startup incubator from San Francisco) track record makes this pattern visible. They were early to back today’s main players when skeptics thought they had it figured out. Companies like Ginkgo Bioworks and Atomwise (more on them later) proved computation could be foundational to biotech and Pharma. Now YC is backing AI Agent startups, showing once again how quickly a new stack of technology crosses into Pharma.

And if you thought leaders like Hudson were just posturing as “tech-savvy” with hyped tools, consider Benchling. One of the most established TechBio incumbents, it recently acquired Sphynx, an AI-agent startup focused on streamlining hypothesis generation and analytics in discovery. By weaving these capabilities into its stack, Benchling reinforced that this isn’t a passing experiment, it’s another layer becoming part of the system.

Now, let’s be clear. AI Agent companies are not “TechBios” in the sense of this deep dive. They are, for now, tools or orchestration engines that Pharma teams can plug in to augment their workforce and automate tasks once dauntingly manual. They represent the kind of technological spark that helps scale approaches to well-known problems in drug discovery.

And while every new wave of technology makes a dent in Pharma, the hundred billion unlocks usually lie elsewhere, closer to solving the big bottlenecks of how drugs are discovered, tested, and developed. That’s where TechBios come in, and where we’ll turn next. For now, think of this section as the apéro: the first cracker to show how the rules of the game have changed.

How TechBios Create (and Capture) Value

If you perplexity (we don’t “Google” anymore in the age of AI) the definition of TechBio, you’ll either get flooded with abstract jargon that means little if you’re not steeped in the field, or a description so simple it could apply to almost anything. Neither helps much.

A more pragmatic lens is to look at TechBios through their value proposition. And this is where it gets interesting. TechBios have been around for over a decade, and in that time their offerings and therefore their positioning in the industry have shifted dramatically.

The SaaS Playbook Enters Pharma

At start, TechBios bore the heavy upfront costs of architecture design, large-scale data acquisition, massive training runs, and inference, all to learn new principles in biology and deliver them as platforms Pharma clients could use for better drug design.

This unlock was driven by compounding forces. On the tech side, models improved as they scaled in size and input, while compute and storage costs fell (Moore’s Law at work). On the bio side, labs and instruments achieved higher throughput, producing exponentially more data at lower cost — the Carlson Curve in genetics being the best-known example. (Sequencing your whole genome cost ~$10 million in 2007; ten years later, it was under $1,000.)

On the demand side, techBios emerged at a time when the status quo relied on rule-based computational methods grounded in rigid theoretical models. These could only handle a limited set of parameters, making it difficult to experiment broadly and ultimately constraining R&D pipeline output. Put in perspective, the stakes of this inefficiency are massive: 69 blockbusters will face patent cliffs by 2030, putting around 236 bio USD at risk.

As Manuel Grossmann the Founding Partner of Amino Collective (Health x Bio Fund in Europe), notes:

“The TechBio space benefits from two fundamental tailwinds: technological advancement and market demand.”

For tech investors, the story clicked. These companies weren’t tied to one risky therapeutic bet; they looked like horizontal software platforms that could scale across the entire industry. TechBios offered Pharma innovation closer with simpler unit economics clean, recurring revenues, faster adoption curves. As Cradle, using language models for protein design puts it:

“One annual software license. No hidden fees.”

No surprise then that capital rushed in. In 2021, right at the cusp of this wave, VC investment in TechBios hit $2.4 billion, with mega-rounds north of $100M backing the promise of programmable biology.

… Opposed To The Longstanding Asset Deal

Until then, most real Pharma innovation was coming from a fundamentally different breed of companies with a focus much narrower and longer time horizons for product market fit.

Biotech companies select a well-studied biological target, develop a molecule against it, and march it through the clinical gauntlet. Their path to value creation is very interactive, reducing uncertainty every step of the way and focusing where prior knowledge give a fighting chance.

Their revenues are therefore less predictable, making take asymmetric bets requiring incredibly specialized knowledge and experience.

Headlines in the domain are hence quite binary. You get the 1 trio USD added Market Cap to Novo from from the GLP-1 of Embark and or failures of expected block busters for Alzheimers.

Pharma companies are in that sense expert in M&A deals for to power their innovation, estimated 65% of its revenue come from these operations. The size of deals made here are often quite substantial, getting back to Car T in the 2010, Roche bought Poseida Therapeutics, a San Diego-based for US $1.5 billion November last year.

… Moving into Co-Development And Blurring The Lines

As the TechBio field matured, one lesson became clear: benchmarks alone aren’t enough.

Validation metrics carefully crafted to showcase model performances gets the initial traction but Pharma ultimately values assets, and without them TechBios struggle to show true impact.

The economic logic makes the difference obvious. A pure platform play might reach a few hundred million in enterprise value. But the real butter in this industry sits with assets, Pharma’s trillion-dollar market cap rests on drugs that make it through the clinic. Without assets, TechBios miss the home run and risk falling outside the venture playbook entirely.

This is what pushed the industry toward co-development. Instead of selling platforms as tools, TechBios began striking deals that shared both risk and upside: upfronts, milestone payments, royalties. Late exemple of this is Creyon Bio AI signing 1 bio USD in milestone deal with Lilly

As Manuel Grossmann of Amino Collective puts it again:

“Focusing purely on providing tools as products or services can often be challenging, since the exit potential tops out in the low hundreds of millions — often misaligned with the VC model.”

This is where the difference between Techbio and Biotechs gets blurry. As the former starts developing their own drug running validation, toxicity and even clinical to out-license as assets, the latter becomes more and more tech enabled and building with open source models from industry like RosettaFold.

The TechBio Playbook Has Emerged

On top of that comes the platform. This is where raw data turns into usable insight. In Recursion’s case, it’s the RecursionOS, an operating system for biology that fuses automated labs with ML models to map complex biology. That’s what Pharma pays for. The economics here look like $150M upfronts, R&D milestones, tiered royalties, exactly the Roche and Genentech partnership structure. At this stage, platforms prove they can de-risk discovery for others.

But the real prize sits in assets. Once the platform works, you push it into your own drug programs: new targets, new molecules, lead optimization.

This is where TechBios flip into biotech economics. Out-licensing assets to Pharma brings upfronts plus large milestone packages, and potentially royalties if the drug hits the market. It’s higher risk, but it’s also where exits climb from hundreds of millions into the billions.

That’s the sequence: data → platform → assets.

Closer to Humans: The Next Big Opportunity in TechBio

Hitting Eroom’s law in translating assets to clinics

If Moore’s law promises exponential gains from technology, Eroom’s law (Moore spelled backwards) reminds us that drug discovery has stubbornly resisted that curve. For decades, the cost of bringing a new drug to market has roughly doubled every nine years, even as compute and data scaled exponentially. AI-driven TechBios were supposed to break this trend and accelerate discovery, lower costs, and flood the pipeline with new medicines. In its early day’s, Recursion was going with something like a 100 drugs in 10 years.

And to some extent, they have delivered. Programs from Insilico or Recursion show how AI can compress preclinical timelines from five years down to 18–30 months. Costs are lower, throughput is higher, and in silico tools have expanded the space of molecules Pharma can explore.

But reality is that most AI-first drugs are still aimed at well-known targets, and once they reach the clinic, they face the same bottlenecks as traditionally developed drugs. Phase II proof-of-concept success rates hover at ~40%, unchanged.

Back to Eroom’s law in action, the bottleneck has shifted downstream. The graph from speed invest tells the story nicely.

Early discovery (target validation, compound screening, lead optimization) accounts for ~25% of costs, the bulk of time and money is lost in Phase II and Phase III, where failure rates spike and costs per molecule can exceed 20–25% of the total.

Functional Data Is the Missing Piece

Why? Because our translational models are still inadequate proxies for human biology. Drugs fail not because they weren’t optimized enough in silico, but because they don’t behave as expected in humans, showing weak efficacy, unexpected toxicity, or adverse effects that outweigh benefits.

Conversely regulators are now pushing for more personalized approaches: genotyping, deeper disease phenotyping, and companion biomarkers to better stratify patients.

That means the next opportunity isn’t about yet another molecule generator. It’s about building the translation layer: generating functional, human-relevant data at scale.

Two pillars stand out:

• Bench side. New experimental systems like organoids and organ-on-a-chip can capture human biology more faithfully than animal models, giving us early readouts of drug response in tissue that resembles real patients. it can be high-dimensional functional data (cells content imaging)
• Bedside. Richer molecular profiling of patients to capture complete responses to interventions across all biological layers. The omics data, reflects physiological responses from the gene expressed to the protein inhibited till the end metabolite produced.

This is the frontier TechBios have yet to tackle.

Proprietary datasets from in vitro, in vivo, or in silico work aren’t enough, because by design they remain at a distance from real human complexity.

Reminder, the demand is still there as the patent cliffs of 2030 are not going anywhere.

The Funding Gap: Bench Traction, Bedside Wide Open

The common denominator in TechBio is always the same: proprietary datasets.

On the bench side, we’re already seeing how this can play out. Just last month, Parallel Bio raised $21 million to push forward a new model for immune drug discovery.

Their platform combines organoids and AI is set to generate massive proprietary datasets of immune responses. This ‘Immune system in a dish’ allows simulate how drugs behave across populations and verify candidates in vitro before they ever enter the clinic. The company dates back to 2021, but recent series A show their gearing up for growth and points to serious answers to the translation problems from Capital Interest.

The story on the bedside is very different. Here, the prerequisite is well-characterized patient data of omics like genomics, proteomics, metabolomics, deep clinical phenotyping. Not really the type of data you can engineer in your lab with enough wetware and hardware.

Pharma companies guard their clinical trials data as part of their asset. Biobanks have the scale needed but primarily share it with research partners and academics or monetizes them directly, selling access to screened samples and metadata at high prices. Their funded by goverments and charitable organizations around projects with defined partners within a consortio that have their for privilege access.

Hospitals typically generate only small, fragmented cohorts a few hundred patients, often disease-specific and far from the scale needed to train robust models.

And once TechBios push into later stages like preclinical or Phase I, costs spike: recruiting patients, managing trial sites, and running protocols and more tailored to big Pharma economics.

In the West, shrinking patient pools for many chronic diseases add yet another barrier driving the cost further up.

This imbalance explains why most visible TechBio innovation so far has come from the bench. Benchside players like Parallel Bio are proving you can generate your own data and own the feedback loop.

On the bedside, by contrast, barriers remain high and that leaves the space wide open.

The real question is not if bedside innovation will emerge, but where.

And it may well be that the answer lies outside the traditional Pharma hubs

In Africa The Bottleneck Was Always Here And Now There a Real drivers for change

Translation is now recognized as the great bottleneck of drug discovery worldwide. But in Africa, it has always been the bottleneck.

Not in developing drugs, but in applying them.

Most medicines were discovered and validated elsewhere, then imported with little understanding of how African populations would metabolize or respond to them. The result is a structural mismatch: Africa accounts for 18% of the global population and 20% of the disease burden, yet fewer than 3% of clinical trials take place on the continent, most of them concentrated in South Africa and Egypt.

This gap is not trivial. Drug absorption, distribution, metabolism, and excretion (the ADME framework) are heavily influenced by genetic variants, especially in liver enzymes like CYP-450, which remain poorly characterized in African populations.

In theory, Africa’s extraordinary genetic diversity should have been a global advantage for understanding variability in drug safety and efficacy. In practice, it was ignored.

As Professor Kelly Chibale of the University of Cape Town has argued:

“If you really want to have confidence in a clinical trial, it must start in Africa. Why? If it works in Africa, there’s a good chance it’ll work somewhere else, because there is such huge genetic diversity.”

Then came COVID-19. The pandemic was a turning point, mobilizing governmental, NGO, and international funding to build sequencing labs, train scientists, and set up data infrastructure.

In my opinion, the Africa Pathogen Genomics Initiative (Africa PGI) became emblematic of this shift.

The first 10,000 SARS-CoV-2 genomes from Africa took 375 days; the next 10,000 just 87 days; the following 10,000 only 24 days. Today, all 54 African countries have sequencing capacity, and African scientists identified two of the world’s five variants of concern.

For the first time, Africa showed it could operate at global pace when given the tools.

These investments were catalytic and revealed what had long been latent:

Africa is not just a recipient of medicines but a potential engine of translational science.

The infrastructure layer, built with public and philanthropic support (like the Bill and Melinda Gates Foundation), is now enabling a broader ecosystem: regulatory frameworks like the Africa CDC and the African Medicines Agency, scientific hubs such as H3D in Cape Town, and new hardware capacity supported by corporates like Thermo Fisher’s Centre for Innovative Research in South Africa.

From here, the snowball is rolling. What began with genomics is already extending across the translational stack. In Ghana, new medicinal chemistry capacity has positioned the country as only the second on the continent (after South Africa) able to run early-stage compound design, linked into the pan-African Drug Discovery Accelerator.

This is big, because the continent can now de-risk potential assets.

Pharma is of course watching closely. Roche’s African Genomics Program is sequencing tens of thousands of African genomes through local biobanks. Sanofi’s partnership with DNDi shows how compounds de-risked in Africa can enter global pipelines.

And demographics strengthen the logic: Africa’s population is set to nearly double by 2050, while non-communicable diseases like diabetes, cardiovascular disease, and cancer will become leading causes of death by 2030 which is the same conditions driving Pharma pipelines worldwide.

The Continent Is Full Of Bright Tech Minds

But data infrastructure alone is not enough; translation also depends on whether there is talent capable of making sense of the data.

COVID revealed this too: it was an African-born (Tunisia) AI company, InstaDeep, that helped BioNTech build the Early Warning System able to flag >90% of WHO-designated SARS-CoV-2 variants an average of two months before their official classification.

The company had already been working with BioNTech on personalized cancer vaccines, and post-acquisition it continues to run as an independent AI lab powering BioNTech’s drug discovery, improving AlphaFold-like protein folding in immunology to designing next-generation mRNA cancer vaccines.

The $700 million acquisition in 2023 was not only the largest AI deal outside the U.S. at the time, but also a watershed moment for the continent. As co-founder Karim Beguir put it in a recent podcast interview:

“our initial motive was to prove that young Tunisians, young Africans could innovate and compete at the highest level”

The significance goes beyond one company.

It validated Africa’s AI talent density, which is being built from the ground up through grassroots, community-led efforts. Initiatives like Masakhane, a volunteer-driven movement advancing natural language processing for African languages, or Deep Learning Indaba, cited globally as a model for how to mobilize a continent around machine learning, are emblematic of this bottom-up energy.

I saw it myself at Applied Machine Learning Days Africa 2024 in Nairobi, where more than 3,000 participants gathered across three days mostly researchers, innovators, and students taking responsibility for local problems and showing how AI can answer them.

This effort-led culture is now being matched with hardware too infrastructure. Microsoft has launched its first Azure cloud region in South Africa, enabling GPU-grade compute to stay on the continent, while Nvidia and Cassava are building an AI factory in Johannesburg, with expansions planned for Kenya, Egypt, Morocco, and Nigeria.

Early Signs, Real Ventures

It’s one thing to say the infrastructure and talent are here but the real test is whether it yields actual companies.

And the signs are already showing. A new class of TechBios is taking shape, raising money, and doing the first thing every good TechBio does:

… drum roll, you should know it by now…

Building proprietary datasets.

The support system is forming too. OneBio, a Cape Town venture studio, closed a $47M Series A to back founders at the biology–technology edge.

Villgro Africa in Nairobi has already incubated 40+ health and life science startups and unlocked $18M in follow-on capital. These are strides stimulate the Techbio ecosystem and in part, to close Africa’s translation gap with venture tools.

And the startups coming out of this wave are telling. I thought I would share my personal pick here. Start-ups I can map on the playbook trajectory.

Yemaachi Biotech in Ghana raised $3M from YC, Tencent, and LoftyInc to build the world’s most diverse cancer knowledge base, sequencing samples across the continent to power precision oncology. As founder Yaw Bediako put it:

“We’re looking at trying to understand cancer in the African diaspora — African American, Black British, and continental Africans — the first initiative of its scale. You can’t say you’re studying a disease if you don’t include the most diverse population on the planet, which is the Black population.”

BioCertica in South Africa, backed by Pronexus and the Gates Foundation’s I3 program with a $2.2M seed, runs consumer genetic tests but is really playing the long game of building the first African polygenic risk database.

And Bixbio, part of OneBio’s portfolio and an Illumina Accelerator graduate, assembled the largest reference dataset ever from Southern Africa, nearly 400 high-quality genomes across eight ethno-linguistic groups.

Even newcomers like Pandora Biosciences are starting on the same path, building chronic disease datasets designed for drug discovery.

And just this summer, the signal got even stronger. In June 2025, Revna Biosciences, a Ghanaian precision medicine startup, announced a landmark partnership with AstraZeneca. Within months, EGFR (gene coding for cell growth protein) biomarker testing integrated into Ghanaian cancer centers, oncologists trained in precision protocols, and the rollout of one of AstraZeneca’s targeted therapies for lung cancer patients.

For a sub-Saharan market that has historically had near-zero access to this kind of precision oncology, that’s nothing short of historic.

As Revna’s CEO Dr. Derrick Edem Akpalu put it:

“This collaboration exemplifies how a synergized biomedical ecosystem such as RevnaBio’s can help address long-standing institutional voids that have limited access to advanced molecular diagnostics and targeted therapies in this region.”

It’s a textbook case of a TechBio going from data and diagnostics to being a direct bridge for global Pharma into Africa.

None of this is random. Data-first plays are the starting point of TechBio always.

In the West, consumer genomics followed the same arc: 23andMe built a database of 15M genomes, went bankrupt, and still got snapped up in 2025 by Regeneron for $256M because Pharma wanted the dataset.

Tempus, sitting on 20 petabytes of oncology data, signed a $160M licensing deal with Recursion to train AI models for biomarker discovery and patient stratification.

The lesson is obvious: even before a molecule is in sight, the data itself is valuable enough to Pharma. Africa’s first TechBios are now running that playbook and they’re doing it from the most diverse human dataset on the planet.

The Stakes for Africa x TechBio

Case Study: 54gene — The Right Start, The Wrong Turn

54gene was supposed to be Africa’s genomics moonshot. Founded in 2019 by Dr. Abasi Ene-Obong, the company set out to fix the glaring gap where less than 3% of global genomic data came from Africans despite the continent holding the greatest genetic diversity on earth. Backed by Y Combinator, Adjuvant Capital, and Cathay AfricInvest, it raised $45M across three rounds and quickly became the poster child for African TechBio.

The model at first was exactly what you’d expect from a good TechBio: start with the data. 54gene partnered with 10 of Nigeria’s largest hospitals, built a biobank that grew past 100,000 patient samples, and focused on high-value cohorts like cancer, cardiovascular disease, diabetes, and sickle cell.

This was the right first play: position as an enabler for hospitals and research centers, pile up proprietary datasets, and generate revenue through paid Pharma collaborations. In other words, service-led first, platform-led later — the same arc followed by U.S. genomics pioneers like 23andMe.

Then came COVID. 54gene pivoted into diagnostics, scaling mobile labs and at one point driving Nigeria’s daily testing capacity from 100 to over 1,000. Revenues spiked — over $20M from COVID testing — but the pivot also pulled the company away from its core playbook. Instead of doubling down on turning its biobank into translational insights with AI, it spun up Seven Rivers Labs, a costly diagnostics arm. The bets didn’t pay off.

By 2022, as COVID demand collapsed, 54gene was caught between a fading diagnostics business and a stalled genomics mission. Layoffs, valuation cuts, and boardroom fights followed. In 2023 the company shut down operations; by 2025, its assets, including the biobank of 100,000 Nigerian genomes were up for sale at just $3M, before a Lagos court froze the deal amid lawsuits between founder and investors.

The story matters because it shows how fragile the trajectory can be.

Imagine if instead of diagnostics, 54gene had invested its datasets into AI models to map dosage differences for African populations, identify new drug targets, or partner on stratified clinical trials. That’s the road from platform to assets, the road that makes a TechBio a unicorn.

Dr. Ene-Obong seems to agree. His new company, Syndicate Bio, is now doubling down on the same thesis but with AI built in from day one partnering on cancer genomics in Nigeria and aiming to turn Africa’s diversity into global drug discovery.

It’s the continuation of the playbook 54gene set in motion, but with the missing piece restored.

Why it matters

Of course, there will be ups and downs. That’s normal for any frontier field. The difference in Africa is that we don’t get unlimited shots on goal. Every story compounds. A success like InstaDeep pulls in investors and Pharma attention; a stumble like 54gene makes them hesitate.

The opportunity is real, the infrastructure and talent are in place, but the responsibility is heavier. What some see as Africa “lagging behind” is actually a strength:

we can study how the TechBio playbook unfolded elsewhere, skip the false starts, and adapt it to our own context.

The lesson from 54gene is in a sense avoiding the hype from the unprecedented achievement set in the continent but rather, stick to the basics: data first, then AI, then assets.

Do that, and the next African TechBio unicorn isn’t just possible;

it’s inevitable.

TechBio x Africa Manifesto: The Playbook for Cracking the Translation Bottleneck was originally published in Included VC on Medium, where people are continuing the conversation by highlighting and responding to this story.

The news came without fanfare. No product demo, no benchmark leaderboard, no viral announcement thread.

Two months ago, OpenAI made two major healthcare appointments:

Daniel Etra from Instagram as Head of Healthcare Product Strategy, Ashley Alexander who spent years at Doximity watching physicians struggle with administrative work, took the newly created role of Vice President of Health Products.

Anyone paying attention understands what this signals.

Times of partnering with healthcare are over. Now Open AI is moving in.

There was clearly a buildup. First came HealthBench in May 2025: 5,000 simulated medical interactions evaluated by 262 physicians across 60 countries. Then GPT-5, showing measurable improvements in clinical accuracy.

Then, in July this year, the pilot that made investors, in Africa, particularly pay attention.

For me this, news feeds right into the AI community running (and sad) joke:

Is OpenAI going to kill my startup?

But which startups, exactly? Why Africa particularly?

Because Large Language Models (LLMs), as per the Lancet, open a new chapter in Digital Health to improve the quality of care. The promise is simple. Decentralize access to clinical knowledge. Reduce errors when doctors are overwhelmed. Answer health questions for populations far from facilities. Improve care quality, delivery and experience without adding more physicians you can’t hire anyway. This promise matters everywhere…

But it matters most where the gap is widest.

Digging into the Mastercard report on AI opportunity in healthcare this year we can quickly grasp the picture. Sub-Saharan Africa has the world’s lowest life expectancy and weakest coverage of essential health services. Morocco for example operates with 7-8 doctors per 10,000 people, 1 in Kenya. Physicians routinely manage 60 to 100 consultations per day with almost no clinical decision support.

Which brings us to the central question of this piece:

Is LLM enabled digital health in Africa a venture case?

This is the most realistic and close ground approach when thinking about the impact a technology can have. Is there a market for it?

TL;DR: LLMs’ Moment in Africa’s Digital Health

• Elephant In The Room: Health-tech Is Not The Sexy Sector For VC in Africa. Healthcare funding collapsed 70% from $212M to $65M in 2024 (40% fewer deals: 52→31). Healthcare ranks 7th across African VC sectors behind fintech, enterprise, ecommerce, cleantech, agritech, and mobility. It captures less than 4% of total venture capital deployed since 2019, the lowest level since 2018.
• The 1:100 Ratio Nobody Wants to Say Out Loud Sewu-Steve Tawia (Jaza Rift) estimates the donor-to-VC money ratio at 1:100, maybe worse. Non-VC capital dominates 54–67% of deals at every stage, peaking at 67% for critical $5–10M growth rounds where pure venture should lead based on traction. Only 3 of 9 growth rounds closed as pure VC.
• One Of Africa’s Biggest Healthcare Exit for Investors Still Needed $12M in Development Debt: LeapFrog’s Goodlife Pharmacy exit (19 stores in 2017 → 150 locations serving 2M consumers by 2025) became Sub-Saharan Africa’s largest PE-led retail pharmacy exit. The largest disclosed check came from Proparco (French DFI) as development debt in 2022, not venture equity. Even the exit that proved the model works required DFI capital to scale.
• Where Does My Check Go? Portfolio Breakdown of 69 Companies Across 19 Countries: Analysis reveals 75% operate phygital models (clinic networks + digital layers), just 8% are pure ecommerce. Primary care infrastructure dominates: pharmacy (16%), primary care (14%), telemedicine (13%) = 43% of all companies. Treatment & Care Delivery represents 59% of use cases, System Infrastructure 20%, Prevention & Education 21%. Revenue models: B2C 45%, B2B 20%, B2B2C 15%.
• Sizing The Opportunity LLMs Open & Betting on Infrastructure: McKinsey estimates GenAI can unlock $1.4B-$2.4B annually in African healthcare (80% relates to agentic systems). Apply 23.4% CAGR and the opportunity approaches $17B by 2030. Intron Health exemplifies infrastructure play: 3.5M audio clips covering 300 African accents, deployed in 30 hospitals across 5 markets, cutting radiology reports from 48 hours to 20 minutes. Their $1.6M pre-seed underwrites a $160M outcome at 100x returns.

Side Note: We assume in this deep-dive the reader if familiar with the fundamentals of what Large Language Models and the incredible worldwide adoption they have when put in commercial products. We will use LLM as umbrella term for simplicity including vision (vi-LLMs) and text (Speech2Text and Text2Speech) sharing same training, scale and architecture paradigm. We are not including diffusion models (generate images or videos) otherwise have used GenAI as a term instead.

Let’s Narrow Our Scope And Define Digital Health:

A bit of housekeeping first: we need to level-set our definition of digital health and establish what falls within and critically, outside our scope. Healthcare systems comprise healthcare providers, insurance companies, government agencies, and patients working together to deliver care. Digital health, in this context, refers to the digital tools and platforms that enable, optimize, or transform how these actors interact across the care continuum you can look up the JazaRift 2024 for more)

However, LLMs allow us to take a fresh stance on categorization our guiding principle centers on where this technology creates transformative impact, not rigid sector boundaries.

We structure our analysis around three core dimensions.

Health Area Category follows Stanford’s GenAI Healthcare framework, distinguishing between maternal-newborn-child health (MNCH), sexual and reproductive health (SRH), communicable diseases like HIV/AIDS and tuberculosis, non-communicable diseases (NCDs) including diabetes and cardiovascular conditions, mental health, health systems strengthening (HSS), primary care, and specialized services.

Care Continuum Stage maps where companies intervene: prevention and education initiatives that keep populations healthy, diagnosis and triage tools that identify conditions, treatment and care delivery that manages illness, monitoring and follow-up that tracks progress, or system infrastructure that enables all of the above.

LLM Integration tracks deployment readiness from companies built natively around LLM technology, to those actively integrating it, to organizations positioned for future adoption. Here we further classify companies as either:

1. LLM-Native (built around technology): Voice-to-text medical documentation, multilingual health chatbots
2. Actively Integrating (adding to existing platforms): Clinical decision support, automated triage
3. LLM-Ready (positioned for adoption)Digital infrastructure + user bases

What we explicitly exclude: pure hardware manufacturers without service delivery integration, wellness and fitness applications without clinical validation, medical tourism platforms, and healthcare facilities without digital transformation pathways. Critically, we also exclude companies where LLM integration offers marginal rather than transformative impact our lens focuses on use cases where this technology fundamentally alters unit economics, unlocks previously unviable business models, or enables scale that was impossible before.

Compiling Companies To Ground Our Analysis

Having defined our scope and criteria for digital health we decided to compile a list of players to power our analysis and capture bottom up trends in funding, opportunities and potential gaps.

As such we tracked funding announcements, company profiles, and operational updates from major African tech and healthcare publications including TechCrunch, TechCabal and specialized newsletters (Africa Health Ventures or Condia) covering the Jan 2023– Nov 2025 period.

We share this list as potential investors might be interested in tracking incumbents or looking to chip in…

We surfaced 69 African (not impressed? wait till you understand the funding ecosystem below) digital health that met our inclusion criteria and systematically tagged across the three dimensions of our analytical framework. We cover 19 countries headquartered in Africa or operating primarily in African market including less represented countries like Senegal, Côte d’Ivoire, Cameroon, Zimbabwe, Ethiopia, Tunisia, Malawi or Zambia.

As comparison point, a search on Crunchbase with Africa and cutoff year of 2020 with all companies tagged Telehealth which arguably can capture 4 out of care continuum subcategories returns 28 hit.

A word of caution, there are clear limitations with this approach. First, this only captures companies for which there has been an announcement of fundraising (deal signal) or a major milestone hit (like scaling operations) and therefore captured in the sources mentioned. Second there can be geographic bias from the language of the media for instance underrepresenting Francophone West Africa and Portuguese-speaking markets with less English-language coverage.

Along the deep-dive we will gradually extract insights from this database to substantiate the few hot takes (and there are some) we make.

And the first one comes right now;

Elephant In The Room: Health-tech Is Not The Sexy Sector For VC in Africa

African health tech just had its worst year on record. While fintech celebrated funding up 59% in 2024, healthcare collapsed. Deal counts dropped from 52 to 31, a 40% decline. Funding crashed 70%, from $212M to just $65M (Partech 2024). AVCA’s numbers show it even worse: 27 deals worth $43M, down 78% year over year. That’s 22% of healthcare’s average funding during 2021 to 2023.

Healthcare ranks seventh across African VC sectors, behind fintech, enterprise, ecommerce, cleantech, agritech, and mobility. The sector’s small share gets even smaller when you look inside. AVCA breaks Healthcare into two categories: “Health Care Equipment & Services” and “Pharma, Biotechnology & Life Sciences.” (Shameless self-plug: I wrote a DeepDive on Techbios in Africa if you want more than one)

Digital health being the focus of this article sits in that first bucket. It’s a slice of an already thin slice.

Between 2019 and 2024, healthcare as a whole captured less than 7% of total venture capital deployed on the continent. This is the sector’s lowest funding level since 2018, and the numbers keep dropping. Digital health specifically? Probably less than that 4%.

But the need is obvious to most and is going nowhere, stating the obvious 70% of the world’s youth will be African by 2050 this must put some pressure to act… But if not VC who is funding?

The 1:100 Ratio Nobody Wants to Say Out Loud

In a conversation with Sewu-Steve Tawia, Managing Partner and Chief Investment Officer at Jaza Rift Ventures, he dropped a number that stopped me cold:

“The ratio of donor to VC money in African healthtech? It’s probably 1:100. Maybe worse.”

One hundred dollars of grant, DFI, and philanthropic capital for every dollar of venture.

Healthcare investments in Africa run on aid budgets, foundation grants, and development finance. It does not run on venture capital or private equity. All of these funding sources operate on fundamentally different timelines, incentives, and success metrics than commercial investors.

In July this year, Gates fundation pledged $ 200B to go directly to Africa, the amount specifically allocated to these topics is not disclosed but the chair of the foundation called out leaders to

“Seize the moment to accelerate progress in health and development through innovation and partnership.”

I think it time to nuance. If you think of the structural issues the continent is facing when it comes to health care, those funds do not go against innovation grounded in realistic markets nor compete with VC investments, on the contrary they are enablers.

Customer Funder Mismatch

Perhaps most perniciously, donor capital trains founders to optimize for the wrong customer. When grants fund 100x more than equity rounds, the customer is not the clinic director or the patient. The customer is the program officer at USAID (before cuts), Foundations or worse governments.

Sewu-Steve explained the problem with a simple gesture. He held up one hand showing the grants. The other hand showed the startups. Then he fit them together like puzzle pieces.

As a Moroccan, two headlines immediately came to mind.

First: Morocco secured $600M from the World Bank with a large focus on healthcare. Second: the country announced its Health Vision 2030 ahead of Gitex Future Health 2026. The plan includes and calls for innovation for use cases like smart hospitals and AI adoption.

Bottom-Up Reality Check

So we decided to test Sewu-Steve’s 1:100 claim. We pulled our database of African digital health companies and extracted every deal with disclosed funding and visible cap tables. After importing our database into Crunchbase, 45 companies with full investor lists and total funding amounts were recovered. We then categorized the close to 120 investors by splitting them into two buckets: VC-only deals (pure venture, accelerator) versus Non-VC deals (anything involving grants, DFIs, foundations, debts, or impact funds accepting sub-market returns).

I recognize this is not the most comprehensive sample for doing analysis of funding rounds or investor’s reports like Partech but it was a way to guesstimate rather fairly the capital structure in field that is usually the most precisely addressed in those same reports (remember less than 7% of the total funding).

The headline number was indeed intriguing. 58% of African digital health deals include non-VC capital. Not as nice-to-have co-investors bridging to the next round. As the majority funding source. 26 of 45 deals required grants, development finance, or philanthropic capital to close. Pure venture-backed deals? The minority is at 42%. Let that settle for a moment. More than half of African digital health funding comes from sources that don’t expect market returns. Sounds systemic rather than a temporary gap that ecosystem maturity will fix.

The trend analysis per stage brought different lens to it. Non-VC involvement ranges from 54% to 67% across every deal size, never dipping below the majority threshold. At sub-$1M seed rounds, 54% of deals include non-VC capital. Then comes the most damning stage: $5–10M growth rounds, where companies should be proving product-market fit and attracting pure VC based on traction. Instead, 67% of deals at this stage include non-VC capital. Only three of nine growth rounds closed as pure venture.

This finding was very intriguing and got me to look into it. Other instruments like debts have been gaining prominence. Also there is a nuance here, including signifies that top lead investors include non VC like investors and stories like AXA Investment Managers leading Helium Health Series B are still a reality.

On another note, these numbers contrast a lot with earlier times of the market in 2023 when grants accounted for less than 10% of the funding invested.

As part of this deep dive, also releasing here the list of compiled investors for founders out there!

Side note: The financial rounds of the different companies can easily be retrieved by uploading the companies on Crunchbase provided you have access. Not owning that data we preferred not to share the output of manual extraction.

So when I asked Sewu-Steve to contrast the capital structure with the number of opportunities, hypothesizing that there might not be that my companies to fund after all. His answer was categorical:

There are misconceptions among Investors about opportunities in Digital Health in Africa, not a lack of them.

And that is what we are about to see in the following section, there are indeed success stories for the VCs that can see.

One Of Africa’s Biggest Healthcare Exits Still Needed $12M in Development Debt

Despite the funding drought, the underlying market fundamentals tell a different story. Africa’s digital health market stood at $5.11 billion in 2025 and is projected to grow at a 23.4% compound annual growth rate until 2030.

In this context, LeapFrog’s Goodlife Pharmacy exit proves the math works when you build right. They entered in 2017 when Goodlife operated 19 stores. By exiting in early 2025, the chain ran 150 locations serving 2 million consumers annually across Kenya and Uganda. CFAO Healthcare, backed by Toyota Tsusho Corporation, acquired full ownership in what became Sub-Saharan Africa’s largest PE-led retail pharmacy exit outside South Africa.

Here’s what matters: Goodlife validated a model most VCs dismissed as too capital-heavy, too operationally messy, too grant-dependent for venture returns.

Even Goodlife’s cap table tells the same story as our 55% statistic. Of the $12M in disclosed funding, the largest check came from Proparco, a French development finance institution, as debt financing in March 2022. Not venture equity. Development debt. The company that just delivered Africa’s biggest healthcare exit needed DFI capital to scale.

Let that register for a moment.

So what model generates those returns while serving low-income populations?”

What did Goodlife crack that made it such a success?

The “Bricks And Clicks” or “Phygital” Model

Bricks and clicks model is not a healthcare invention. Retail figured it out first when pure e-commerce players started hemorrhaging cash and traditional stores watched foot traffic vanish. The concept is (again) simple, physical locations provide tactile experience, immediate gratification, and trust through presence. Digital layers provide convenience, personalization, and operational intelligence. Neither works alone at scale. Combined, they create something customers actually want and investors can actually exit.

McKinsey’s retail research found that stores integrating digital across merchandising, marketing, and operations saw sales double. The interesting component of the model resided in owning physical assets generating higher margins, and digital intelligence and channels to make those assets efficient.

Getting bricks and clicks right requires three elements. First, real time inventory integration so customers see what exists where. Second, a customer data infrastructure that personalizes both digital and physical touch points. Third, operational systems that treat stores as fulfillment nodes, not just retail endpoints. Most retailers nail one or two. Winners nail all three.

Healthcare adds a fourth element with clinical integration across the care continuum. Physical locations become care delivery nodes for treatment and diagnosis, and digital channels handle prevention education, triage, and monitoring between in-person visits. The customer data infrastructure tracks health outcomes alongside transactions, turning each interaction into a longitudinal patient record that informs both clinical decisions and business operations. This allows bricks and clicks healthcare models to capture value at multiple stages, from keeping populations healthy to managing chronic conditions, which is more than monetizing single transactions like pure retail or pure digital models.

How Goodlife Built Bricks and Clicks at African Economics

Goodlife’s physical layer started with asset-light discipline. Rent land instead of buying. Build prefab stores instead of custom construction. Manage inventory through just-in-time procurement instead of warehousing. This kept capital expenditure contained while scaling across Kenya and Uganda. The stores themselves became the competitive moat, not through size but through strategic placement serving both low-income and high-income populations in the same markets.

The digital layer came in three components. First, an e commerce platform for ordering and delivery. Second, WhatsApp sales channels that meet customers where they already communicate. Third, the myGoodlifeClub loyalty program that now has 500,000 members tracking purchase history and enabling personalized offers. Point Of Sale (POS) inventory management connected every store to central visibility, turning the chain into a distributed fulfillment network.

The integration happened through partnerships expanding service offerings without capital deployment. Tibu Health provides teleconsultations. HealthX offers laboratory services (Africa Health Ventures, 2025). Goodlife owns the customer relationship and the physical touchpoint. Partners provide specialized clinical services. The customer experiences seamless care. The business captures margin at every step.

WhatsApp is the connective tissue making bricks and clicks work, customers order refills while commuting, check drug availability before visiting stores or receive personalized health reminders without downloading another app. WhatsApp sits on every smartphone with internet in East Africa already. In Uganda, it represents 10–15%, Kenya 40–45% of the overall population with nearly 100% of the user having internet penetration. Goodlife turned that ubiquity into infrastructure. This becomes critical when we talk about where LLMs fit into African digital health economics, because the interface layer already exists and 2 million consumers already use it monthly.

okay, so long detour to get you up to speed with the dynamics at play. Let’s get back on our feet and talk LLMs.

Where LLMs Enter: Intelligence Layer To Scale Phygital Economics Beyond Regions

LLMs solve the core problem that’s kept brick and click healthcare from scaling in Africa: the cost of human intelligence at every interaction. A pharmacist answers the same medication questions 50 times per day. A nurse triages calls to determine who needs urgent care. A clinic administrator schedules appointments, manages inventory, and sends refill reminders. These are pattern matching, information retrieval, and workflow orchestration. Exactly what LLMs do at near zero marginal cost (assuming you do not train from scratch the billion parameters and spend the millions of USD in compute).

The Stanford Center for Digital Health surveyed healthcare leaders in low and middle income countries about GenAI priorities. The top three use cases align precisely with Phygital model economics: 50% prioritized health education and awareness, 44% clinical decision support, and 43% health related behavior change (like adherence to medication prescriptions). These are immediate operational needs that brick and click models must solve to scale profitably.

These capabilities deliver value at each stage:

Prevention: Personalized Health Education at Scale
Cliniva, a Kenya based nurse led hybrid healthcare model, serves 54,000+ patients (80% women) through physical clinics plus a WhatsApp prevention assistant. The AI delivers personalized health tips, nudges, and prompts based on clinical history, behavior, and preferences. No app download. No clinic visit unless needed. The result is high patient retention serving low-income populations through preventive care that traditional models cannot afford to deliver manually.

Triage: Routing Patients to Right Care Level
MDaaS Global operates 23 diagnostic centers connecting low-income Nigerians to affordable healthcare through its “Ask Beacon” AI powered WhatsApp chatbot. The system provides triage assessment, medication support, and appointment management, reducing barriers to verified care facilities. Patients describe symptoms via messaging. The AI determines urgency and routes to appropriate care level, from self care guidance to immediate diagnostic center booking. Human clinical time focuses on actual diagnosis, not information gathering.

Treatment: Medication Adherence Through Automated Touchpoints
Audere’s “Self Care from Anywhere” program in South Africa demonstrates LLM treatment support at scale. The WhatsApp AI companion uses locally trained language models with 1,000+ word slang dictionary to maintain culturally fluent conversations about HIV prevention and medication adherence. Users choose conversational personas (older sister, clinician, peer) and interact privately. The system flags high risk disclosures like abuse or suicidal ideation for immediate human escalation while handling routine adherence support automatically.

Follow Up: Continuous Care Coordination
Helium Health, serving 500+ health facilities, 10,000 health workers, and 1 million patients across Nigeria, integrates Turn.io messaging into HeliumOS (electronic health records) and HeliumDoc (patient engagement app) to strengthen appointment management and follow up care. Post treatment monitoring happens asynchronously through automated check ins. Patients report symptoms or confirm recovery via WhatsApp. The system updates clinical records, schedules follow ups when needed, and closes care loops without requiring patients to return for in person visits unless clinically indicated.

Orchestration: The Infrastructure Layer Making It Economically Viable
Behind these patient facing interactions sits operational intelligence managing appointment scheduling across distributed clinic networks, inventory forecasting by location and season, supplier ordering for bulk purchasing optimization, and routine customer service. This is what LeapFrog emphasized in Goodlife’s transformation to

“asset light, profitable business model, with keen focus on improving unit economics via targeted initiatives on product assortment, supply chain optimization”.

and that agentic capabilities can bring.

In this model, LLMs can make the coordination at scale economically viable at African unit economics and get companies closer to the vision all these Phygital companies fit into, which Sewu-Steve well put:

Sizing The Opportunity LLMs Open In Digital Health

Scaling the “Phygital”

McKinsey's May 2025 report on Africa estimates generative AI could unlock $61 billion to $103 billion annually across all sectors, with healthcare representing $1.4B-$2.4 of that total for healthcare sector. While this is not specific to LLMs addition in the click and brick model, it can be further interrogated with looking at funded initiatives for that technology. Stanford's separate analysis of LLM projects in low and middle income countries provides a different lens: 37% of funded GenAI healthcare initiatives target direct-to-consumer applications (health education, behavior change messaging, triage systems), 22% target direct-to-provider clinical tools (decision support, diagnostic aids), and 41% focus on system-level interventions (public health surveillance, workflow optimization, medical research). So roughly 80% of that number relates to agentic systems deployed at scale. Now if you factor in the CAGR mentioned earlier in the deepdive on 5 iterations, you reach around $ 17B opportunity. Okay, this is an approximation under a fair amount of assumption but still provides a sense of how much we are talking about.

Betting on the LLMs system infrastructure

Now, the infrastructure layer supporting these applications represents a distinct opportunity: provider-facing tools for clinical documentation, voice-to-text medical records, translation across African languages and accents, appointment scheduling, and inventory management. In this different segment Intron Health exemplifies more of B2B play with their speech recognition platform trained on 3.5 million audio clips covering 300 African accents, deployed in 30 hospitals across five markets. Their services have allowed for instance to cut the time to deliver finalized radiology reports from 48 hours to 20 minutes. The company’s July 2024 pre-seed raise of $1.6 million, led by Microtraction with participation from Jaza and Africa Health Ventures, reflects investor conviction in this model. At typical venture returns of 100x for pre-seed stage investments, Intron’s backers are underwriting a $160 million outcome.

Where Does My Check Go?

The Phygital thesis and LLM opportunity are theoretical until you look at what’s actually getting funded. We analyzed the 69 African digital health companies with active funding to curate opportunities looked at the spread by business model, geography, and technology readiness. Here’s the portfolio breakdown. The principle was to flag which incumbents were ready to integrate, integrating or not joining the party at all. Moreover, attempt at positioning them along the care continuum and Phygital spectrum in order to best guide potential decisions.

Birds view on the database:

75% operate phydigital or digital first models combining clinic networks, pharmacy locations, or diagnostic centers with digital coordination layers. Pure ecommerce pharmacy represents 8%, traditional clinics without digital infrastructure 12%, specialty telemedicine 5%.

Primary care infrastructure dominates vertical focus. Pharmacy (16%), primary care (14%), and telemedicine (13%) represent 43% of all companies. Specialty care (fertility, mental health…) represents 6% combined.

Revenue models split across consumer and provider. B2C companies selling directly to patients represent 45%. B2B companies selling like infrastructure play to providers represent 20%. B2B2C platforms connecting both represent 15%. The remaining 20% operate hybrid models.

Use cases concentrate in two areas. Treatment & Care Delivery represents 59% (direct patient care, medication dispensing, diagnostics, chronic disease management). System Infrastructure represents 20% (electronic records, inventory management, appointment scheduling, insurance processing). Prevention & Education represents 21%.

Geographic concentration is there. Four markets capture 65% of funded companies: Nigeria (23%), Kenya (14%), South Africa (14%), Egypt (13%). The remaining 35% scatter across 15 other markets, with Ghana at 7% and no other country exceeding 4%.

Stress Testing the Thesis

Medsaf contrasts the “Phygital” play

The phygital thesis sounds elegant on paper, but execution failures reveal where theory meets ground truth. Medsaf’s 2024 shutdown offers the clearest test case. The Lagos based startup raised over $2 million from Y Combinator and Techstars to digitize pharmaceutical procurement for Nigerian hospitals and pharmacies. The model looked defensible: B2B sales to institutions, solving counterfeit medicine problems, backed by credible investors. By January 2023, Medsaf ran out of cash after a failed Series A, citing “mounting debts and significant unpaid receivables from hospitals.” The acquisition deal fell through by November. Full time staff were laid off without back pay.

What killed Medsaf was the customer funder mismatch. Hospitals and pharmacies operate on 90 to 120 day payment cycles, if they pay at all. Medsaf was burning venture capital to finance working capital for customers who treated them like a free credit line. COO Rotimi Lawal acknowledged “dismal payment behavior of hospitals” as a core issue. Founder Vivian Nwakah later reflected: “We were before our time.” But timing matters less than unit economics. You can’t build a venture backable business when your customers are systematically unable to pay on commercial terms.

The entire system runs on structural underfunding, which flows directly into how companies like Medsaf get paid (or don’t).frican governments average 7.4% of budgets on health (less than half the 15% Abuja Declaration pledge), while development assistance dropped 70% between 2021 and 2025. Unlike fintech, with its rapid transactions and network effects, healthtech depends on partnerships with hospitals, pharmacies, or government institutions. That process is slower and more complex.

Closer Look At LLM Implementation In Reality

The LLM healthcare opportunity in Africa faces genuine technical, commercial, and infrastructural barriers that could keep most companies stuck in permanent pilot mode.

The infrastructure isn’t there yet. Africa holds less than 1% of global data center/cloud capacity, with 66% concentrated in South Africa. Toby Olatunji, Co Founder of Intron Health and lead on the AfriMed QA project, a portfolio company of Jaza Rift, explained the gap in a podcast interview with African Health Ventures:

“One of my friends called me the day after the GPT 4 demo, and it was like, oh, it looks like Intron is going to cease to exist. Like, GPT 4 has done everything… I reminded him that the day before, we’re working with this big hospital, and the problem we’re trying to figure out is how to configure their network. That’s it.”

There’s also no regulatory infrastructure. High-income countries have post market surveillance systems to catch safety signals. Across most of Africa, that infrastructure doesn’t exist yet, creating risk that unsafe products reach patients before anyone knows they’re broken.

The specialization gap runs deeper than language. Even Intron Health’s voice models when switching between medical specialties because the distribution of conditions and cases may not be represented in training data. What you expect from a physician differs profoundly from a clinical officer, trained nurse, midwife, or community health worker. Where are the datasets for those cadres?

The funding model remains more pilot than pattern. Jacaranda Health has scaled their PROMPTS maternal health service to 526,000 users in Kenya, answering 10,000 questions daily. But they’re still expanding to Ghana, Nigeria, and Eswatini on pilot funding. Viamo’s Ask Viamo Anything reached 32,000 users across six African countries in 2024, yet remains in “late pilot” status despite their non AI platform serving 27 million users. Funding also reflect this pilot phase with smaller check initatives trying to push technology from providers like Meta’s Llama Impact Grant awarded $20,000 each to five companies or Turn.io’s accelerator which gave $500,000 total to 10 organizations.

Bilal Mateen, Co Founder of Sisonke Biotech and former Wellcome Trust program officer, warned in the same interview:

“Donors are fickle. And I say that as a former donor… We have this brief window where the philanthropic community is willing to put their catalytic investments behind Gen AI, LLM, AI at large for health… And if we don’t figure out how to prove the value proposition quickly and transition that cost to either national governments, public services or the investment market… we’re going to fall into the same translational valley of death that we have every single time.”

The bottlenecks are real. But they’re being addressed by serious organizations with patient capital. The question becomes whether VCs are willing to match their deployment timelines to the actual 5 to 10 year commercialization path, rather than expecting enterprise SaaS multiples by year three.

Closing the loop

So, is OpenAI going to kill African health startups? Only the ones solving problems that are already solved. Which startups exactly? The ones building generic chatbots without localization, without understanding that “lamb chops” means STI symptoms in South African clinics, without the infrastructure that makes LLMs clinically useful in contexts where doctors see 87 patients a day.

Why Africa particularly? Because the gap between need and resources creates the conditions where LLMs matter most. But also because the infrastructure is being built right now in high demographic and economic growth market. Bio RAMP’s AfriMed QA covering 15,000 questions across 32 specialties. Afrispeech capturing medical conversations across 300 accents. Digital Square’s localized datasets in Kenya, Nigeria, Rwanda. Jacaranda’s UlizaLlama in five African languages. Each becomes rails the next wave builds on.

The datasets exist.

The benchmarks exist.

Is LLM enabled digital health in Africa a venture case? The answer depends on the model and the timeline. LLM open a big value creation opportunity and even early small scale pilots like Penda’s show already 16% fewer diagnostic errors across 40,000 visits at $0.84 per user. The Goodlife proved Phygital now works but it still it tool 12 years to get an exit there. Healthcare is indeed a tricky sector with structural bottlenecks, still the first principles of this market and the technology enabled make it hard to conclude with a negative.

My personal opinion here is that when infrastructure players like Intron Health build ecosystems of solutions, that’s when real clustering starts and technology integrates in both directions.

That’s when venture math works best.

But as we saw the rails are being laid and some trains are already running.

LLMs’ Moment in Africa’s Digital Health: Who Builds, Who Pays, Who Wins was originally published in Included VC on Medium, where people are continuing the conversation by highlighting and responding to this story.

The longevity fever is reaching Africa. In October 2025, Kenya opened East Africa’s first dedicated longevity clinic. Egypt launched a National Health Tourism Platform and broke ground on a 40 feddan medical tourism investment zone near the Pyramids. Morocco surpassed 18 million tourists by November 2025 while a new longevity center in Casablanca began offering regenerative medicine.

Longevity spent decades in academic obscurity became investable after 2013, when scientists published twelve “hallmarks of aging” that gave entrepreneurs something to actually target. Billions flowed in. Altos Labs launched with $3 billion. Retro Bio chased a $5 billion valuation. Swiss clinics now charge CHF 48,000 for optimization programs. The science matured. The capital followed. And now the geography is expanding.

But Africa presents a puzzle. Consumer appetite is real: 67 percent of African respondents expressed willingness to participate in healthspan research, compared to 41 percent of Europeans who declined. The demographic tailwinds are extraordinary and Africa’s age dependency ratio is declining while every other region ages. And yet over half of longevity clinics globally still lose money. The gap between stated interest and actual purchasing behavior is vast. The prerequisites for mass market adoption remain elusive.

The question is not whether Africa will participate in the longevity economy. It is which entry points offer attractive returns now, which require patience, and which are mirages. The answer depends on understanding a critical distinction: wellness tourism integration versus pure play clinics. One is ready. One is not. The timing window for the first is narrowing. The second may be a decade away.

TL;DR

• South Africa proves the model. USD 4 billion wellness sector, doubling by 2030. Longevity safaris at Steenberg, Grootbos, Royal Malewane already work. Domestic market provides occupancy stability.
• Kenya tests the next phase. Limitless Clinic (October 2025) is East Africa’s first clinical longevity offering. Its performance reveals whether medical integration scales beyond luxury spas.
• MENA offers near term deployment with hard deadlines. Morocco’s 2030 World Cup forces infrastructure investment. Egypt’s Pyramids medical tourism zone and UAE capital flows create specific entry points. Capital before 2030 captures visibility; after competes in a crowded market.
• Pure play clinics serving local populations are 5 to 15 years out (personal take). Three prerequisites missing: middle class scale, therapy price compression (from $15,000 to $2,000 to $5,000 range), and category awareness.
• Egypt is closer (5 to 10 years, personal take). Nigeria is further (10 to 15 years). Egypt has UAE connectivity and relative stability. Nigeria has unmatched demographic scale but volatility and infrastructure gaps.
• The limits are real. Over 50% of longevity clinics globally lose money. Divide stated consumer interest by three to get realistic demand. Hotels claiming wellness often underdeliver (21 of 24 luxury brands in one survey). Each operator must educate its own customers because no shared quality frameworks exist. Tourism dependent models are exposed to travel volatility.
• Signals to watch: Limitless Clinic customer mix. Precision Wellness Egypt expansion beyond tourists. Morocco hotel pipeline with wellness positioning.
• Bottom line: Fund wellness tourism integration now. Monitor pure play prerequisites. Deploy on local markets when middle class purchasing power and price compression converge.

Before we start, I small trip down memory lane is important to understand the DNA of a field that navigates between the limits of molecular biology and the fantasies of life long youth. I am personally avid of history and I am always fascinated of how it does not repeat itself but always rhymes ( full on Dan Carlin’s Hardcore History lately)

And as often with technology, it starts with fundamental research breakthroughs. The following is handpicked from a broader read I highly recommend from longevity international, 2018 report (It is 675 pages long, so I figured you would appreciate a summary).

If you are not into history that much want to get to the heart of it feel free to skip this section.

The Longevity Field in Context

The Science Comes First

For most of the twentieth century, aging research occupied a peculiar position in medicine: respected enough to exist, but too speculative to attract serious resources. Scientists understood that organisms aged. They did not understand why, or whether anything could be done about it.

The intellectual foundations accumulated slowly. In 1954, Denham Harman proposed the free radical theory of aging, suggesting that unstable molecules produced during normal metabolism gradually damage cells over time. Think of it like rust accumulating on metal.

In 1961, Leonard Hayflick discovered that human cells can only divide a limited number of times (between 40 and 60 divisions) before they stop, a boundary now called the Hayflick limit. This was the first proof that aging is programmed into our cells, not simply wear and tear. The United States formalized its commitment to the field in 1974 by creating the National Institute on Aging within the National Institutes of Health.

These discoveries built fundamental knowledge still far from building an industry, science was ahead of the technology. Applications being still far out of sight, “geroscience”, the study of aging’s biological mechanisms, retained something of a fringe reputation well into the 2000s.

2013: The Year Everything Changed

Two events in 2013 transformed longevity field and made it venture outside academic into commercial routes.

The first was scientific. Researchers published a landmark paper in the journal Cell identifying nine “hallmarks of aging,” later expanded to twelve. These hallmarks are the specific biological processes that cause our bodies to deteriorate ( I think you should here about some of them, so here they are. I am keeping it to half) :

1. Genomic instability: accumulating DNA damages through errors like with repair mechanism or exposure to mutagenesis factors
2. telomere attrition: the protective caps on chromosomes shortening
3. epigenetic alterations: it modulates in how genes are expressed and therefore downstream activation/inactivation of key metabolic processes
4. loss of proteostasis: the body’s protein quality control failing
5. mitochondrial dysfunction: our cellular power plants breaking down
6. cellular senescence: cells that stop dividing but refuse to die, releasing inflammatory signals and others.

This framework gave scientists and entrepreneurs a shared vocabulary. Instead of vaguely “fighting aging,” they could now target specific mechanisms.

Simone Gibertoni, CEO of Clinique La Prairie, a flagship institution in consumer focused longevity interventions, captured the psychological shift: “The fact that we now know that epigenetics, driven by lifestyle, can influence the way we age as opposed to relying on genetics, has increased people’s awareness that they can actually do something about how they age.” This is an important idea. The echoes of these discoveries started to reach the publics’ ears, and we will drill down on this later.

As this was not enough, the second event was commercial. Google launched Calico, short for California Life Company, with the stated mission of extending healthy human lifespan through technological means. TIME Magazine put it on the cover with the headline “Can Google Solve Death?”

The announcement recruited Arthur Levinson, former CEO of biotechnology pioneer Genentech and chairman of Apple, as chief executive. Calico also attracted Cynthia Kenyon, a renowned geneticist whose work on roundworms had demonstrated that single gene mutations could dramatically extend lifespan.

This was the beginning of a trend, with billionaires spinning of aging focused companies, with insane valuations and hiring “crème de la crème” scientists and executives.

The New Era

Google’s move triggered a cascade. In 2014, Calico partnered with pharmaceutical giant AbbVie, each committing $250 million with an option for $500 million more (they now parted ways, will understand why).

The same year, J. Craig Venter, the scientist who had led the private effort to sequence the human genome (25th anniversary this year), founded Human Longevity Inc. to apply genomic analysis to aging. Venter’s mission statement was direct:

“Aging is the single biggest risk factor for virtually every significant human disease… our goal is to solve the diseases of aging by changing the way medicine is practiced.”

He recruited Franz Och, head of Google Translate, as chief data scientist, signaling that longevity would be as much a computational challenge as a biological one. (Shameless plug here for my article on how the trend of programmable biology unfolded and what it means for Techbios and Africa)

The most dramatic capital deployment came in January 2022, when Altos Labs emerged from stealth with $3 billion in committed funding from investors including the one and only Jeff Bezos, making it one of the largest launches in biotechnology history.

The company assembled what Fierce Biotech called a “dream team” leadership with amongst many, Shinya Yamanaka, the Nobel laureate whose discovery of cellular reprogramming (a technique to revert adult cells to an embryonic state) underpins much of modern longevity science.

The pattern persists today. In January 2025, Retro Biosciences, a San Francisco biotech startup with the stated goal of adding ten years to healthy human lifespan, began raising a $1 billion Series A round. OpenAI CEO Sam Altman, who previously provided the company’s entire $180 million seed round, is participating again. CEO Joe Betts-LaCroix told the Financial Times he wants to move fast, discovering and developing a drug “in the 2020s.”

From a risk factor to reversing aging in roughly a decade

Pierre-Edouard Sottas, CEO of xLongevity, a clinic network operating in Switzerland and expanding into emerging markets including India, describes the field’s evolution in three phases.

Ten years ago, the focus was tackling aging in the context of chronic disease. Medicine addressed conditions individually: heart disease, diabetes, cancer, Alzheimer’s. Each had its own research programs, drug pipelines, and clinical protocols. Aging is the common risk factor linking them, but the healthcare system treated symptoms rather than the underlying process.

Five years ago, the conversation shifted to slowing aging. Researchers began targeting cellular mechanisms directly. Drugs like metformin, originally developed for diabetes, and rapamycin, an immunosuppressant, showed unexpected effects on aging pathways in laboratory studies. The goal became extending healthspan (will talk about it), the period of life spent in good health, by decelerating biological decline.

Now, according to Pierre-Edouard, what he sees attending conferences is that it has shifted again: now to solve aging directly. Rather than targeting individual cells or diseases, researchers are addressing systemic dysfunction. The ambition is no longer incremental improvement but fundamental intervention and potentially to reverse it.

Where the Science Stands Today

I figured you might want to have a birds view on what is happening, get a few buzz words for your next coffee conversation or board meeting small talk so here it comes.

The Hevolution Foundation, a Saudi backed organization (interesting right?we will ding into that later) that has deployed over $400 million to healthspan research in three years, provides a useful survey of current scientific progress in its Global Healthspan Report.

Senolytics represent one of the most promising therapeutic categories. As we age, some cells enter a state called senescence: they stop dividing but do not die. These “zombie cells” accumulate in tissues and secrete inflammatory signals that damage surrounding healthy cells. Senolytic drugs selectively eliminate these senescent cells. Over thirty clinical trials investigating senolytic agents have been completed, are underway, or are planned for various conditions (go to clinicaltrials.gov, you can even see the yearly rampup).

GLP-1 receptor agonists, originally developed for diabetes and weight loss, have emerged as unexpected candidates for broader healthspan effects. These drugs, marketed under names like Ozempic and Wegovy, mimic a hormone that regulates appetite and blood sugar. Dr. Eric Verdin, President and CEO of the Buck Institute for Research on Aging, calls them potentially “the first global anti-aging drug that we have.” The two largest producers of GLP-1 drugs have gained over one trillion dollars in market value since 2021.

Epigenetic clocks offer new ways to measure biological age. While your chronological age counts years since birth, your biological age reflects how much your body has actually deteriorated. Scientists have developed techniques that analyze DNA methylation patterns (chemical modifications to DNA that change with age) to estimate biological age.

Cellular reprogramming, (explained above) has advanced from laboratory proof of concept toward potential therapeutic application. Partial reprogramming, which rejuvenates cells without fully reverting them to an embryonic state (which would risk tumor formation), has demonstrated the ability to restore mitochondrial function and reduce inflammation in animal studies, with lifespan extension observed in mice.

CRISPR gene editing, the technology that allows precise modification of DNA sequences, has been applied to aging research. Screens have identified over 300 gene modifications that can rejuvenate neural stem cell function in aged brains, pointing toward pathways that might preserve cognitive function.

Dr. Peter Diamandis, Founder and Executive Chairman of the $101 million reward XPRIZE competition (from the hevolution foundation), summarizes the outlook:

“The next decade will witness game changing technologies that hold transformative potential for extending healthspan.”

The last word of that sentence is critical for framing the promises of an entire industry. It is time we explain what “healthspan” actually means and the implications for the consumer eye!

Extending Healthspan rather than Lifespan

Making The Distinction

Medicine has extended how long we live. It has done far less to extend how long we live well. The gap between lifespan and healthspan, the years spent in good health rather than decline, represents one of the largest unaddressed problems in global healthcare.

In developed economies, the final decade of life often involves chronic disease management, diminished mobility, and cognitive decline. Healthcare systems built around treating sickness struggle to prevent it. Preventive care remains systematically underfunded relative to treatment, creating a structural opening for new approaches.

The economic stakes are substantial. Global costs of chronic obstructive pulmonary disease alone are expected to reach $4.8 trillion by 2030 according to the Hevolution Global Healthspan Report, 2024. A one year extension of healthy life expectancy in the United States could generate an estimated $40 trillion in economic value. These figures explain why governments are beginning to pay attention. Australia has allocated $545 million to preventive health research over the next decade. Singapore’s Healthier SG reform now provides personalized health plans for citizens over 40. The UK’s Our Future Health program, with two million participants, has become the country’s largest health research initiative.

While not Africa specific, these numbers exemplify the productivity gain and economic upside if healthspan was to close the gap. The chronic disease plague is also raging in our continent and these maths would very much apply too. Moreover, the famous silver crisis with the aging of western population driving the need for action is also reaching Africa and quite strongly, the number of people above 60 has doubled in sub-sahraian countries in 15 years. As we will see the economics of the longevity do not make sense yet for the continent but the issue is inexorably coming and we will interrogate further the trends that would allow burst of this industry for locals.

Consumer Demand Is Real and Global

The consumer shift toward wellness is measurable and accelerating. According to McKinsey Future of Wellness Survey, 2024, in the United States, 84 percent of consumers say wellness is a top or important priority. In the United Kingdom, that figure is 79 percent. In China, it reaches 94 percent. This is a global phenomenon, not a Western indulgence. The Hevolution Foundation’s 2024 global survey found that 49 percent of consumers expressed interest in longevity enhancing products or services, up from 32 percent in 2023. Two thirds of surveyed medical professionals now encounter patients asking about healthspan interventions at least once a month, with one third reporting weekly inquiries.

Regional variations reveal where demand runs hottest and you would be surprised! The fever of healthspan extension is spreading to our regions.

The Middle East and North Africa stands out: 35 percent of MENA respondents were definitely interested in longevity solutions, compared with the global average of 19 percent. Moreover, sixty seven percent of African respondents said they were open to volunteering for healthspan research, compared with 56 percent globally and just 41 percent in Europe who actively declined participation.

When asked about virtual healthspan consultations, 58 percent of African consumers cited better access as a key motivation, versus global averages focused on cost and convenience.

Calibrating for Hype

Survey data generally overstates actual purchase behavior and. This is a consistent finding across consumer research, and longevity is no exception. Pierre-Edouard Sottas, CEO of xLongevity, offers a useful calibration from his experience at Biostarks: in 2018, 90 percent of surveyed consumers said they would pay 200 Swiss francs for comprehensive blood testing. Actual conversion was a fraction of that. His rule of thumb: divide stated consumer interest by three for realistic market sizing (Interview with Pierre-Edouard Sottas, xLongevity, 2024). Applied to the 49 percent global interest figure, this suggests roughly 16 percent of consumers represent genuine near term demand.

Even with this discount, the numbers point to a substantial addressable market. Sixteen percent of a global consumer base still represents hundreds of millions of potential customers. The question becomes which segments are most likely to convert, and what they actually want to buy. The answer challenges intuitive assumptions about who cares most about aging.

The Demographics Behind

The primary customer for longevity services is not who you might expect. Conventional wisdom would point to consumers over 50, people closest to the problems of aging and most motivated to address them. The data shows the opposite. The core customer segment is 30 to 40 year olds who are already health and wealth focused. The 50 plus demographic comes last according to Pierre-Edouard. This inversion makes sense once you understand the psychology. Younger affluent consumers treat health optimization as a form of status. Older consumers, paradoxically, are often in denial about aging or resigned to its inevitability.

The spending data confirms this pattern. In the United States, Gen Z and millennials represent 36 percent of the adult population but drive 41 percent of annual wellness spending. Consumers aged 58 and older make up 35 percent of the population but only 28 percent of wellness spend (McKinsey Future of Wellness Survey, 2024). Nearly 30 percent of Gen Z and millennials report prioritizing wellness significantly more than the previous year, compared with 23 percent of older generations. Younger consumers also purchase across a wider range of discretionary wellness products, from health tracking devices to IV drips to wellness retreats. They are more experimental, more influenced by social media, and more willing to pay premium prices for science backed solutions.

The cultural shift is real. Five years ago in places at the edge of technology like California, wealth was displayed through material possessions. Today, health has become the status signal. “Mitochondria is the new money,” as Sottas put it. For affluent younger consumers, optimization is identity. This creates a specific customer profile: educated, high income, proactive about health, skeptical of traditional healthcare, and willing to pay for personalized solutions. Understanding this demographic is essential for anyone building in the space.

What This Means for Africa and Emerging Markets

Africa’s demographic structure presents an interesting alignment with this customer profile. The continent is the only region where age dependency ratios are expected to decrease through 2050 while the rest of the world ages. This means the healthspan opportunity in Africa has a fundamentally different shape. It concerns optimizing the productive years of a young, growing workforce rather than managing elderly decline. The 30 to 40 year old segment that drives longevity spending globally is precisely the demographic that will dominate Africa’s consumer class in the coming decades.

The caveat is important: this alignment only becomes commercially relevant as middle class purchasing power matures. High research participation willingness does not equal ability to pay Swiss clinic prices.

Africa’s healthspan market will develop along a different trajectory, likely starting with wellness tourism that captures international spending before pure play clinics can target local consumers. The consumer demand exists. The business model must meet people where they are.

These consumers, whether in Zurich or Nairobi or Dubai, share common characteristics. They want proactive intervention, not reactive treatment. They want personalization, not one size fits all protocols. They want measurable outcomes, not vague wellness promises. They are willing to pay, but they expect results.

Understanding what they are buying, and what falls outside the scope of credible longevity services, is the subject of the next section.

What’s In, What’s Out

Biopharma and Geroscience R&D are out

This analysis does not cover companies focusing on developing the technology for translating the latest science we mentioned earlier. Essentially incumbents running clinical trials for aging therapeutics, senolytic drug development, or gene therapy platforms. One reason for that is the mismatch with the African Market. Most of these companies sit a the bleeding edge of technology and as we hinted earlier sit in very singular place, Silicon Valley or Singapore.

The second reason for that is regulatory. The picture is still blurry, no pathway exists to get an anti aging drug approved in the United States because aging is not classified as a treatable disease. This single fact reshapes the entire investment calculus. Without disease classification, reimbursement from insurers or state medical systems is impossible, making it difficult to generate the multi billion dollar sales that justify venture scale returns. As Sergey Jakimov of LongeVC put it: “The regulatory framework is very clear that in order to prove anything in this world, you must have a disease indication, and a clinical trial design. People have been investing in shiny theses like curing ageing. That’s a great idea, but it doesn’t work for venture capital.”

Those investments require stem and focus on different regions with different timelines, risk profiles, and exit strategies.

Digital Platforms and Wellness Apps Alone Are Out

Companies with a play of digital biomarkers combined with AI recommendations are largely driven by western world. Companies like Vitality, MyHealthspan or Whoop monitoring heart, sleep and activity and proposing lifestyle interventions like rest time or adding sleep time.

They also sit on the expensive end of the spectrums. Tech based health and wellness services may be marginalizing the populations with the greatest needs. In Africa and much of MENA, digital adoption lags physical infrastructure. This means widespread smart watches, high band internet and electricity penetration.

This analysis focuses on brick and mortar clinic and hospitality plays where the customer acquisition channel requires physical presence, not app downloads. The digital layer matters for operational efficiency and diagnostics delivery, but it is not the primary investment thesis.

AgeTech and Novel Financial Systems are out

AgeTech includes novel retirement plans, cognitive enhancement products, fintech for the elderly, mobile apps targeting seniors, continuing education platforms, and entertainment designed for older demographics. Novel Financial Systems encompasses longevity index funds, hedge funds, specialized stock exchanges, longevity derivatives, and longevity trusts. Both categories represent legitimate investment opportunities with their own dynamics. They require different expertise, face different regulatory environments, and serve different customer segments. Investors seeking exposure to the broader longevity theme should examine these sectors separately. This analysis concentrates on the clinic and hospitality convergence where tourism provides the customer acquisition channel and medical infrastructure delivers the service.

What’s In

Longevity Clinics and Their Service Stack

Longevity clinics occupy a specific position in the healthcare landscape. They fill the gap between reactive sick care, which waits for disease to manifest, and unguided self optimization, where individuals experiment without medical supervision. The service stack has become relatively standardized across markets. Core diagnostic offerings include biological age testing through epigenetic clocks, genetic and genomic analysis, full body MRI scans, DEXA body composition scans, and comprehensive blood biomarker panels. Therapeutic offerings span IV therapies including NAD+ and vitamin infusions, cryotherapy, hyperbaric oxygen treatment, personalized supplement protocols, hormone optimization, and lifestyle coaching with ongoing monitoring.

Hotel Integrated Wellness and Longevity Offerings

The convergence of hospitality and healthspan services represents the second pillar of this analysis. Tourism provides the customer acquisition channel that standalone clinics struggle to build. Two integration models have emerged. In the clinic led model, a longevity clinic establishes itself adjacent to hotel infrastructure, controlling the medical offering while the hotel provides acquisition and hospitality services. In the hotel led model, the hotel owns the wellness journey but brings in longevity expertise to extend its offering. The Estate Hotels partnership with Fountain Life and Clinique La Prairie, and One&Only One Za’abeel featuring the Longevity Hub by Clinique La Prairie, demonstrate this approach. Both models are in scope because they share the same customer economics: capturing wellness tourism spending that averages 38% higher than standard international tourism. Pierre-Edouard mentions talks with Accor and W hotel chains, and integration of one it centers within 200 square meters within hotel properties.

Acknowledging The Aesthetic and Wellness Blurry Frontier In the Scope

The distinction between longevity medicine and aesthetic medicine remains contested. Survey data from Longevity.Technology reveals the overlap: 28% of longevity clinics offer Botox injections, 35% offer hair loss treatments, and 38% offer facial rejuvenation procedures. Andrea Maier, former president of the Healthy Longevity Medicine Society and cofounder of a private longevity clinic, acknowledges this directly. The blurring serves a commercial purpose. Aesthetic treatments generate immediate, visible results that satisfy customer expectations while longer term healthspan interventions work invisibly over years. The revenue from aesthetics can cross subsidize the more capital intensive diagnostic and therapeutic infrastructure.

Investors should approach this boundary with pragmatism rather than purism. Clinics that generate sustainable revenue from aesthetic services while building genuine healthspan capabilities may prove more durable than those pursuing scientific legitimacy at the expense of commercial viability. The test is whether the aesthetic revenue enables investment in evidence based protocols or whether it becomes the entire business. Over 80% of surveyed clinics report oversight by medical doctors with more than ten years of clinical experience. Many prescribe medications off label for aging, including metformin and rapamycin analogs. This medical foundation distinguishes longevity clinics from spa operations even when their service menus overlap.

To summarize, this analysis applies the healthspan lens to the clinic and hospitality opportunity in Africa and MENA. We examine operators delivering predictive, preventive and personalized (P3 medicine) components, specifically personalized diagnostics, preventive therapies, and outcome tracking, through physical locations that leverage tourism infrastructure. With scope established, we can now examine what longevity clinics actually do and why people pay for them.

Longevity Clinic Value Proposition

What Patients (Or Clients?) Actually Receive

The service stack described above translates into a specific consumer journey. A client entering a longevity clinic typically begins with comprehensive diagnostics:

1. blood panels measuring dozens of biomarkers
2. epigenetic testing to determine biological age
3. body composition analysis
4. cardiovascular assessments.

These generate a baseline. The clinic then produces personalized protocols combining nutrition guidance, supplement regimens, exercise prescriptions, and in some cases pharmaceutical interventions like metformin or rapamycin analogs prescribed off label. Clients return periodically for reassessment, tracking whether their biological age is declining relative to chronological age, whether inflammatory markers are improving, whether metabolic function is optimizing. The value proposition is early detection and course correction: identifying dysfunction before it becomes disease, intervening while the trajectory remains malleable.

Pricing Architecture

The price architecture for this journey spans three orders of magnitude. At the ultra premium tier, Clinique La Prairie charges CHF 30k — 50k for week long programs delivered by 50 physicians using proprietary formulations. At the accessible premium tier, Swiss clinics like Ayun offer comprehensive diagnostic packages starting at CHF 1.5k — 3k, with the Longevity Center in Zurich pricing its supreme assessment at CHF 14,500 for approximately 30 different tests including biological age and 3D body scanning. Entry level check ups begin around CHF 1,850. The xLongevity model, operating through B2B2C partnerships with hotel chains and wellness centers targets approximately 400 CHF per person per month (recurring) for its integrated offering of testing, coaching, supplements, treatments, and digital tracking.

The Longevity Pyramid Framework

A November 2024 paper in Frontiers from Martinovic et al. in Aging introduced the Longevity Pyramid, a conceptual framework for evaluating interventions by evidence strength. This can help consumers figure out the offering that most suits their appetite for outcomes and risk.

The pyramid has five levels, with the most validated approaches at the base and the most speculative at the apex. Understanding this hierarchy helps investors and consumers assess what clinics are actually selling.

Base layer consists of diagnostics and analysis. Biomarker panels, epigenetic clocks, wearable data integration, and physiological measurements form the foundation of longevity medicine. This layer has the strongest evidence base because it involves measurement rather than intervention. Knowing your biological age, inflammatory status, or metabolic efficiency is informative regardless of what you do with that information.

Lifestyle interventions layer: exercise protocols, dietary modifications like caloric restriction or Mediterranean eating patterns, sleep optimization, and stress management. WHO guidelines recommend 150 to 300 minutes of moderate intensity aerobic activity weekly, and observational studies show a reverse J shaped association between exercise and mortality, meaning benefits increase up to an optimal threshold. These interventions have decades of epidemiological support, though randomized controlled trials measuring longevity outcomes remain sparse simply because such trials would take decades to complete.

Dietary supplements layer: NAD+ precursors like NMN, spermidine, resveratrol, quercetin, and related compounds. The Frontiers paper notes these are “promising in preclinical studies” but “require long term, large scale randomized controle trials (RCTs) to establish efficacy and safety in humans.”

Most clinic supplement protocols operate in this evidentiary gray zone: mechanistically plausible, supported by animal models, but not yet validated for human healthspan extension.

Pharmacological and non pharmacological layer. Metformin, the diabetes drug showing potential geroprotective effects, is currently being evaluated in the TAME trial (Targeting Aging with Metformin) among participants aged 65 to 79. Rapamycin was the first pharmacological compound shown to extend lifespan in mammals, but Martinovic et al.s note its “translational implications for human longevity are still under investigation.” Non pharmacological interventions like cryotherapy, hyperbaric oxygen therapy, and infrared sauna fall here as well. Studies show these can improve specific biomarkers, particularly in athletes, but most fail to demonstrate lasting benefits or longevity extension.

The apex layer contains experimental strategies: gene editing via CRISPR, stem cell infusions, mRNA therapies, and tissue engineering. These approaches have “shown remarkable effects in extending lifespan and reducing age related decline in animal models,” but the Frontiers authors caution that “the complexity of human aging, coupled with ethical considerations, makes the direct application of these strategies in humans challenging.” Yet according to MIT Technology Review article published in April this year over one third of surveyed longevity clinics offer stem cell treatments. There is no evidence these treatments help people live longer, and they carry documented risks. The gap between what clinics sell and what science supports is widest at the pyramid’s apex.

Crystallizing the Limits

The most significant constraint facing longevity clinics is not regulatory or financial. It is psychological. Pierre-Edouard Sottas, CEO of xLongevity, frames it directly: people want shortcuts. They don’t want diminishing biological aging, a gradual measurable decline tracked through epigenetic clocks. They want to feel physically younger. The emotional pull is toward dramatic transformation, not incremental optimization. This insight explains why the market resembles 1995 rather than 1998 in technology terms: infrastructure is being built, but the transformative product, the iPhone moment, hasn’t arrived. Biological age clocks, first developed in 2013, give clinicians the ability to measure cellular aging with increasing precision. A client can learn their cells are 52 when they are chronologically 48, or track their biological age declining over successive visits. This is scientifically meaningful. But knowing your biological age doesn’t make you feel ten years younger. The moonshot intervention that bridges measurement and sensation does not yet exist.

This gap explains the persistence of aesthetic treatments in longevity clinics. Botox produces visible results within days. Hair restoration treatments show progress within months. Facial rejuvenation delivers mirror confirmation of improvement. These satisfy the consumer desire for perceptible transformation in ways that cellular optimization cannot. The revenue from aesthetics may cross subsidize the more capital intensive diagnostic and therapeutic infrastructure, but the commercial logic runs deeper: aesthetics sell because they deliver what clients actually want to experience. The Hevolution Foundation report acknowledges this tension, noting that the field must distinguish evidence based science from unsubstantiated claims while recognizing that consumer demand often runs toward the latter.

The evidence gaps compound this challenge. Martinovic et al. states plainly that “randomized controlled trials that evaluate the effects of these interventions over extended periods remain sparse.” Human studies on supplements like NAD+ precursors, spermidine, and metformin “are still in the early stages.” Without long term, large scale trials, the practical application of these strategies remains limited, and their effects on healthspan and lifespan are uncertain. Individual variability further complicates matters: genetic predisposition, baseline health, lifestyle factors, and environmental influences all affect how people respond to interventions. Personalized medicine, while a growing field, cannot yet predict these individual outcomes with accuracy.

The standardization void amplifies investor risk. The Hevolution report notes that “standardized protocols and frameworks will be key for the industry to scale”. Demand for standardization exists: 36% of surveyed clinics would change their protocols to match an internationally recognized standard, and 58% would consider doing so with more information. But very few such standard exists. Private companies will likely set de facto standards before regulators catch up, creating interim uncertainty about what constitutes legitimate longevity medicine versus marketing relabeled as science. For investors, this means due diligence must extend beyond financial metrics to clinical credibility: which protocols have evidentiary support, which practitioners have relevant expertise, and which outcomes can be meaningfully measured. The absence of consensus is a structural feature of this market phase, not a temporary gap awaiting imminent closure.

Balancing That With The Formula 1 Analogy

The vacuum left by absent standards may be filled by private enterprise rather than public policy. The Hevolution Foundation draws an analogy to Formula 1: just as racing teams developed anti lock brakes that eventually reached every consumer vehicle, early adopter patients at premium clinics fund the protocol development that broader populations will eventually access. The high price points are not merely exclusionary; they finance the iteration required to validate what works. Pierre-Edouard, puts it more directly: the private sector leads academic research by three to five years in translating longevity science to clinical application. Metformin, rapamycin, and mTOR pathway interventions were in private clinic use long before academic consensus formed. Regulatory frameworks cannot keep pace with the speed of technological advance, and Pierre-Edouard expects standardization to be established by private companies, with governments following afterward.

For investors evaluating this space, the implication is clear, track where private operators are converging on protocols rather than waiting for regulatory clarity that may arrive only after the market has already decided.

Market Landscape

The wellness economy has become one of the defining economic forces of our time. At $6.76 trillion in 2024, it now exceeds the green economy ($5.1 trillion), IT ($5.27 trillion), tourism ($5.07 trillion), and sports ($1.77 trillion) in market size (Global Wellness Institute, 2025). This figure has doubled since 2013 and grown at 6.2% annually over the past five years, consistently outpacing global GDP growth of 4.7%. The projected annual annual growth is at 7.6% through 2029, which would bring the market to nearly $9.8 trillion. For investors seeking exposure to structural consumer shifts, wellness represents a secular tailwind with demonstrated resilience through economic cycles and pandemic disruptions.

Healthspan investment specifically has experienced dramatic volatility. The sector reached an all time high of $8.8 billion in 2021, collapsed to $3.4 billion in 2023, then rebounded to $7.3 billion in 2024 (Hevolution Global Healthspan Report, 2024; Longevity.Technology/Pitchbook data). That recovery, more than doubling year over year, signals renewed investor confidence. The number of deals declined from 279 in 2020 to 231 in 2024, but average deal size increased 77% over the period. This shift reflects a maturing field where later stage clinical investments attract more capital. Later stage VC claimed $2 billion in 2024, up 56% year over year. Private equity resurged from effectively zero in 2023 to $1.5 billion in 2024. The capital is becoming more concentrated in companies with demonstrated progress toward commercialization.

Geographic concentration tells a familiar story with an emerging subplot. The United States hosts 58% of healthspan companies, Europe 15%, and the UK 10%. North America ($2.3 trillion), Asia Pacific ($2.0 trillion), and Europe ($1.7 trillion) together account for nearly 90% of the global wellness economy (GWI, 2025). Yet regional drivers differ in ways that matter for emerging market strategies. In the EU, positive biotech market sentiment drives investment activity, with 44% of B2B investors citing this as a key factor. In MENA, the entry of mainstream investors into the healthspan sector is the primary catalyst, cited by 46% of regional B2B investors compared to only 28% globally (Hevolution B2B Survey, 2024). This distinction suggests MENA’s growth reflects capital allocation decisions by generalist investors discovering the category, rather than specialist biotech momentum.

Investment barriers explain why healthspan remains severely underinvested relative to the scale of the challenge. Biotech overall attracted roughly $90 billion in 2024; healthspan captured only $7.3 billion (Longevity.Technology, 2024). The gap reflects persistent structural obstacles. Lack of public awareness ranks as the top barrier, cited by 59% of B2B investors. Regulatory framework gaps have risen to second position at 46%, up significantly from prior years. Limited industry expertise ranks third, also at 46%, and this constraint is especially acute in APAC and Africa where more than half of investors identify it as a barrier. In the EU and MENA, 49% and 45% of investors respectively report difficulty distinguishing legitimate opportunities from hype (Hevolution B2B Survey, 2024).

Wellness tourism provides the economic logic for longevity services to overcome these structural challenges, particularly in emerging markets. The $893.9 billion market in 2024 represents the fourth largest sector in the wellness economy, accounting for 13.2% of all wellness spending, with projected growth of 9.1% annually through 2029 to reach $1.38 trillion (GWI, 2024). The sector’s defining characteristic is spending intensity. International wellness tourists spend $1,637 per trip on average, 38% more than typical international tourists. Domestic wellness tourists show an even more dramatic premium, spending 137% more than typical domestic travelers. This spending differential explains why wellness tourism’s share of total tourism has grown from 6.3% of trips and 14.2% of spending in 2019 to 8.3% of trips and 17.6% of spending in 2024. Wellness travelers punch far above their numerical weight.

The bulk of this market operates differently than most people imagine. Primary wellness travel, where the destination choice is motivated by wellness, accounts for only 17% of trips and 16% of expenditures. The remaining 83% of trips and 84% of spending come from secondary wellness travel: people who seek wellness experiences while taking trips for other reasons (GWI, 2024). This distinction matters for investment strategy. Building a dedicated wellness destination requires attracting the smaller primary segment. Integrating wellness into existing tourism infrastructure captures the much larger secondary segment. For emerging markets without established wellness destination brands, the secondary wellness opportunity provides a more accessible entry point.

MENA has emerged as the world’s fastest growing region for wellness tourism, a development with direct implications for adjacent African markets. Wellness trips grew by 11.0% annually and expenditures by 15.0% annually from 2019 to 2024, the highest growth rates globally (GWI, 2024). The region has posted the highest post pandemic recovery rate, with wellness trips at 169% and expenditures at 201% of their 2019 levels as of 2024. Wellness tourism expenditures reached $24.7 billion in 2024, up from $12.3 billion in 2019. This growth has been driven by booming inbound tourism in the UAE, Saudi Arabia, Egypt, Morocco, Qatar, Bahrain, and Oman.

Emerging Market Dynamics (“Comps” for Africa)

The Africa longevity thesis does not emerge in isolation. Three distinct models from other emerging markets offer instructive patterns: India demonstrates the power of scale combined with direct payment healthcare; the UAE shows how regulatory leadership can shape an entire regional ecosystem; and the Caribbean illustrates how small jurisdictions can compete through legislative agility. Each reveals structural forces that Africa can leverage, while also exposing prerequisites that must be met before certain models become viable.

India: Scale Meets Payment Structure

India’s appeal for longevity services rests on demographics and payment culture. The country’s 1.46 billion population has a median age of just 28.8 years (Worldometer, 2025), meaning the addressable market skews toward consumers young enough to invest in preventive health rather than reactive care. The middle class is expanding rapidly: PRICE (People Research on India’s Consumer Economy) estimates it grew at 6.3% annually between 1995 and 2021, now representing 31% of the population and projected to reach 38% by 2031. Consumer spending is forecast to rise from $1.9 trillion to $5.2 trillion over the same period. Even a conservative estimate that 20% of the population represents an emerging health conscious segment with discretionary income yields approximately 290 million potential customers. This is the scale logic that makes India compelling. As Pierre-Edouard Sottas of xLongevity observed, the sheer volume of addressable consumers in markets like India transforms unit economics that would be marginal in smaller populations. As Pierre-Edouard pointed out, capturing the emerging middle class of engineers from local tech industry conscious of their health provides the scale you look for this to be economically interesting.

The payment model matters as much as the demographics. India’s healthcare system operates predominantly on an out of pocket basis, with consumers making direct choices about health spending rather than relying on insurance reimbursement. This creates natural alignment with preventive longevity services that rarely fit insurance models in developed markets. Clinicians benefit from an additional incentive structure: in a landscape where generic drug competition compresses pharmaceutical margins, practitioners can supplement income through revenue sharing on the supplements and protocols they prescribe. The combination of young demographics, expanding purchasing power, direct payment habits, and clinician alignment creates conditions for longevity services that may be more favorable than wealthier markets with older populations and insurance gatekeepers

The Out of Pocket Paradox

The counterintuitive finding from emerging market analysis is this: direct payment markets may be better positioned for preventive longevity services than wealthy insurance based systems. In Europe, prevention gets discussed and blood work gets prescribed, but the insurance model remains fundamentally oriented toward sick care. Reimbursement codes exist for treating disease, not for optimizing health in apparently well individuals. Preventive longevity services do not fit this architecture.

In Africa like in India, healthcare operates on direct out of pocket payments. Consumers decide what they value and pay accordingly. When prevention competes for wallet share rather than navigating insurance bureaucracy, it can win on perceived value. The Hevolution Foundation survey captures this dynamic indirectly: 50% of European respondents expressed negative sentiment toward longevity products and services, while MENA respondents (again) showed 35% “definitely interested” against a global average of 19%. Europe’s comprehensive public healthcare may actually reduce perceived need for alternative healthspan solutions. Markets without that safety net show greater receptivity.

UAE as Regulatory Pioneer

Abu Dhabi has moved faster than any jurisdiction globally to establish longevity medicine as a legitimate, regulated category. In 2024, the Department of Health Abu Dhabi licensed the Institute for Healthier Living Abu Dhabi (IHLAD) as the world’s first specialized Healthy Longevity Medicine Centre. This licensing followed development of evidence based clinical guidelines through collaboration between DOH, IHLAD, and the Healthy Longevity Medicine Society. Professor Andrea Maier of the National University of Singapore called it “a tremendous milestone,” noting that “for the first time, a government is embracing the idea that prevention should be the key.” The UAE blueprint demonstrates that governments can act ahead of scientific consensus to create favorable conditions for longevity services. This sets a template that African jurisdictions could adapt. Dubai’s movement toward insurance reimbursement for prevention signals where regional policy may shift over time.

This regulatory leadership matters for neighboring markets. Egypt maintains strong commercial and cultural ties to the UAE. As we will see bellow this shapes investable cases for the continent in this space.

The Bahamas Using Regulatory To Differentiate in Tourism Strategy

Small jurisdictions are competing to become regulatory homes for longevity medicine, and the Bahamas has made the most aggressive move. In July 2024, the country passed the Longevity and Regenerative Therapies Act, with a comprehensive framework covering gene therapies, stem cell treatments, immunotherapies, and advanced longevity interventions. Prime Minister Philip Davis was explicit about the intent: the legislation aims to place the Bahamas at the forefront of global advancements in medical and wellness tourism. The digital monitoring system (LAR-TA) went live in April 2025, creating a structured pathway for therapies not approved by the FDA to be administered under ethical oversight (ZNS Bahamas, May 2025). Deputy Prime Minister Chester Cooper, who also holds the tourism portfolio, described the bill as creating a platform for the evolution of the Bahamas tourism brand from recreation to rejuvenation.

The economic results are already visible. Bryan Johnson, the biohacker who has become longevity medicine’s most visible evangelist, traveled to the Bahamas in 2024 to receive 300 million stem cell injections at Albany Resort, a luxury property co owned by Tiger Woods and Justin Timberlake. Swedish biotech Cellcolabs now operates clinical trials at multiple Bahamian properties, attracting Silicon Valley executives and professional athletes willing to pay $30,000 to $60,000 for regenerative therapies. The treatments occur within a framework designed to provide legitimacy: ethics committee approval, institutional review board oversight, and post treatment monitoring that distinguishes the Bahamas model from unregulated clinics elsewhere.

Business Model of Longevity Clinics

Spoiler Alert: Most Of Them Loose Money Today

According to a 2025 survey by Longevity.Technology covering 82 clinics globally, only 39% reported profitability. Another 30% described themselves as approaching breakeven, while 16% acknowledged operating at a loss. Pierre-Edouard Sottas, CEO of xLongevity, puts the figure starker: more than half of longevity clinics currently fail to generate sustainable returns.

The structural challenge traces to three cost centers that compound against each other.

1. Capex requirements are substantial. Building out a clinic with diagnostic equipment, treatment rooms, and appropriate medical infrastructure demands significant upfront investment.
2. High Opex for physicians creates ongoing margin pressure. Longevity clinics require experienced doctors, and the MIT Technology Review survey found that more than 80% of clinics reported oversight by medical doctors with over ten years of clinical experience. These professionals command premium compensation.
3. Customer acquisition today is still high. The primary longevity consumer is a health conscious individual aged 30 to 40 with disposable income. This demographic is expensive to reach and convert. Traditional healthcare marketing channels don’t apply because longevity services exist outside conventional medical systems. Direct consumer acquisition requires education about a category most people don’t yet understand. Each clinic must essentially build awareness for the entire concept of healthspan optimization before selling its specific offering. This creates acquisition costs that further erode margins regardless of treatment quality or efficacy.

Hotels offer a solution to the acquisition problem

Two distinct integration models have emerged around this solution:

In the clinic led model, a longevity operator establishes itself adjacent to hotel infrastructure, leveraging the hotel’s existing customer flow. The clinic controls the medical offering while the hotel provides acquisition and hospitality services. Pierre-Edouard testifies of centers working with xLongevity pursuing this approach with known brands partnerships with Accor and W hotel groups.

In the hotel led model, the hospitality brand owns the guest relationship and brings in longevity expertise to extend its offering. The Estate Hotels exemplifies this approach through partnerships with Fountain Life and Clinique La Prairie. One&Only One Za’abeel in Dubai features a Longevity Hub operated by Clinique La Prairie. The distinction matters: who controls the customer relationship determines who captures the margin.

The revenue mathematics favor integration. According to HVS hospitality research, spa and wellness services represent 30 to 50 percent of total revenue at dedicated wellness resorts, compared to 7 to 10 percent at standard luxury hotels. Wellness focused properties also achieve longer average stays and stronger midweek occupancy, improving RevPAR. This creates alignment between clinic operators seeking acquisition channels and hotel operators seeking revenue enhancement. The integration solves problems for both parties.

The hospitality industry has a credibility problem that creates opportunity for clinical partners. Luxury Partners conducted proprietary research evaluating 24 leading luxury hotel brands on wellness positioning and delivery. Only three brands delivered on their promises. The remaining 21 underperformed relative to their own positioning, with an average shortfall of 8 points on their scoring methodology. In the worst cases, the gap exceeded 15 to 20 points. A language audit found that vague, indeterminate phrasing outnumbered precise, evidence based language by a ratio of 5 to 1 in hotel wellness content. By comparison, specialist wellness operators showed only a 1.5 to 1 ratio. Hotels are 3.5 times more likely to use imprecise language than dedicated clinical operators. Perhaps most striking: 88% of the 24 brands made no reference to longevity whatsoever. This credibility gap explains why hotels need clinical partners and why clinics that can deliver measurable outcomes will command premium positioning.

Platforms Are Not Subject To Opex And Scale

For operators seeking scale beyond single clinic economics, B2B2C presents a path forward. Rather than building multiple clinics with their associated capex and opex burdens, the B2B2C model enables other operators with diagnostics, AI interpretation, protocols, coaching systems, and supplements. This spreads fixed costs across multiple properties and creates recurring revenue from clinical enablement rather than direct patient services. xLongevity has positioned explicitly in this space. The model addresses the fundamental tension in longevity services: high touch personalization doesn’t scale efficiently, but technology and standardized protocols can extend clinical capacity without proportional cost increases. Existing clinics or wellness centers within hotels have built in distribution that can integrate this platform inside their offering off the shelf. Packaged expertise meets the appetite for differentiation. This model makes platforms like xLongevity emphasize on 360 experiences for the patient proposing complete catalogs and digital ecosystems clinics and hotels alone would have no rationale to build or aggregate across multiple providers. For xLongevity the incentive is in exhaustiveness and ease of integration to justify integration cost and revenue sharing with the “retail” be it clinics or hotels.

Advise For Investors

For investors and founders, the business model realities point toward specific deployment strategies. Capital should flow toward hotel integrated longevity clinics in established tourism corridors, technology platforms enabling multiple properties, practitioner training and certification programs, and partnerships with operators like Clinique La Prairie, Fountain Life, or xLongevity entering Africa and MENA. Capital should avoid standalone luxury clinics without hospitality partnerships, pure digital plays in markets where app adoption lags physical infrastructure, and models dependent on local market demand before tourism channels prove viable. This explains why wellness tourism remains the entry vector for Africa. The tourism channel solves customer acquisition because wealthy international visitors are already present. It solves price sensitivity because tourists spend discretionary money on experiences rather than grudging healthcare expenses. And it builds brand awareness that can transition to local markets as economic conditions mature. The standalone clinic thesis requires prerequisites that African markets have not yet met. The hotel integrated model works with conditions as they exist today.

Where the Fever Lands

Africa’s competitive position rests on structural advantages that cannot be replicated elsewhere. Indigenous healing traditions combined to the continent natural landscapes create an authenticity differentiator that imported Swiss models cannot match. African botanicals including marula oil, rooibos, and shea butter provide ingredients for therapies rooted in centuries of local practice. And the integration of wellness with adventure tourism creates experiences unavailable in clinical settings in Geneva or Abu Dhabi. As Dr. Elie Abirached, founder of Limitless Human, frames the opportunity: “Africa has always been the cradle of humanity. Now we are leading in longevity medicine”.

Longevity Safaris

The existing wellness safari represents Africa’s most mature longevity tourism offering. Global wellness tourism reached $893.9 billion in 2025, with Sub Saharan Africa’s share growing at 17.7% annually and wellness expenditures on the continent recovering to 189% of pre pandemic levels according to 2025 Global Wellness Institute (GWI) report. The model works because it solves the customer acquisition problem that plagues standalone clinics. Wealthy travelers already plan African safaris; adding longevity services captures incremental spend from an audience predisposed to pay premium prices.

South Africa anchors this segment with a wellness sector valued at USD 4 billion in 2022, expected to more than double by 2030. The Western Cape alone reports that 45.2% of visitors engage in wellness activities. Established properties including Steenberg in Constantia Valley, Grootbos near the southern tip, Royal Malewane in the Greater Kruger, and Karkloof Safari Villas in KwaZulu Natal have built reputations combining indigenous African therapies with luxury hospitality. These operators use locally sourced ingredients: marula and neroli healing earth balm for deep tissue massages, raw sugar and salt body scrubs, herbal steam baths, and energy healing rituals drawn from traditions predating colonialism. The domestic market supplements international arrivals, providing occupancy stability that pure tourism plays lack. In this context, local offering like Expand Health or Fore Life Longevity can benefit from this tailwind.

Kenya’s October 2025 launch of the Limitless Clinic at Entim Sidai Wellness Sanctuary in Karen, Nairobi marks the transition from wellness tourism to clinical longevity services. This service stack mirrors what Swiss and Gulf clinics provide, but delivered in a setting where guests can run with Kenyan distance runners, plant trees, learn Maasai beading, and watch elephants from the pool . The Limitless Clinic can represent a proof point in that clinical longevity infrastructure can be profitably integrated into Africa’s existing tourism ecosystem.

The distinction between a wellness safari and a safari with a spa matters for investors evaluating opportunities. A massage overlooking the bush is pleasant but does not constitute a wellness offering. True wellness safaris require multiple pathways to renewal: movement programming, nutritional protocols, mindfulness practices, sleep optimization, and measurable health outcomes. “A wellness safari is a journey that nurtures the mind, body and soul,” explains JB Burger of Thornybush Game Lodge. Properties that can deliver this depth command price points exceeding $1,000 per night and attract high net worth visitors from the UK and US who prioritize sustainability, organic cuisine, and authentic cultural experiences. Properties that relabel existing spa services will disappoint sophisticated consumers and damage the category’s reputation.

Pharaonic Treatment With Egypt as the MENA Gateway

Egypt is positioning itself as the primary gateway connecting Gulf capital and expertise with African scale and cost advantages. In October 2025, Health Minister Khaled Abdel Ghaffar announced the launch of Egypt’s National Health Tourism Platform, a digital gateway enabling international patients to book, coordinate, and manage medical and wellness services with 72 hour visa processing. The government’s explicit target is becoming a top ten global destination for medical and wellness tourism by 2030.

The Giza medical tourism investment zone represents the physical manifestation of this strategy. Located on the Nile in Giza Governorate, the 40 feddan (168,000 square meter) zone will be operational by May 2026. Maxim Investment Group’s Naya Wellness Resort will anchor the development, offering therapeutic services, rehabilitation programs, preventive healthcare, and luxury wellness services adjacent to the Pyramids. The proximity to Cairo and Egypt’s cultural heritage sites creates a tourism multiplier unavailable in purpose built Gulf destinations. Visitors can combine longevity treatments with experiences that make the trip memorable beyond the clinical outcomes.

Precision Wellness provides a proof of concept for evidence based longevity services in the Egyptian market. Founded by Dr. Tamer Degheidy and operating in both Egypt and UAE, Precision Health Group positions itself as “the region’s first evidence backed wellness center”. Moreover, record investment from the UAE in Egypt in touristic infrastructures and mega real estate projects is poised to drive further influx of higher end customers acquainted to a baseline level of longevity services back home.

The Kingdom of Wellbeing: Morocco’s Convergence Moment

Morocco is experiencing a convergence of tourism momentum, infrastructure investment, and wellness positioning that creates a distinct opportunity window. The kingdom topped 18 million tourists by November 2025, exceeding government targets. Officials frame this as a transitional step toward hosting 26 million tourists by 2030, roughly doubling tourism receipts. A $1.5 billion expansion of Mohammed V International Airport will increase annual capacity from 30 million to 80 million passengers. This infrastructure buildout is not speculative and aligned with Morocco is co hosting the 2030 World Cup with Spain and Portugal, creating a hard deadline for compliance with European hospitality standards.

The wellness foundation already exists. Morocco ranks second in MENA for wellness tourism with 2.5 million entries generating $1.55 billion in revenue. The kingdom operates 11 thermal springs, which GWI identifies as among its biggest strengths. Some 1,785 open spas generate $244 million in revenue. The Moroccan National Tourist Office explicitly positions the country as “the country of wellbeing par excellence,” marketing hammams, argan oil treatments, thermal stations, and meditation retreats in Atlas Mountain and desert settings. This is established infrastructure, not aspirational planning.

The emergence of clinical longevity services signals the next phase. Centre Médical Dawam in Casablanca now offers health and longevity check ups, specialized geriatric consultations, regenerative medicine (hyperbaric oxygen therapy, ozone therapy, vitamin IV infusions), aesthetic medicine, physical rehabilitation, and nutritional coaching. This service stack parallels what European longevity clinics provide, delivered in a market where treatment costs are lower and cultural tourism adds experiential value. Morocco’s traditional hammam ritual provides an authentic wellness foundation that modern longevity protocols can extend rather than replace.

The 2030 World Cup creates infrastructure and visibility that wellness tourism will capture. The event requires hotels, transportation, and hospitality services meeting Western standards. These investments will serve wellness tourists long after the tournament concludes. Morocco’s combination of government commitment, existing wellness infrastructure, emerging clinical services, and event driven investment creates conditions for rapid sector development. For investors, the timing window is narrow: infrastructure investments made before 2030 will capture the visibility boost; those arriving after will compete for attention in a more crowded market.

Pure Play Longevity Clinics (Future Thesis)

The second investment model operates on a fundamentally different timeline and risk profile. Where wellness tourism integration represents a near term opportunity with existing infrastructure and proven customer acquisition channels, pure play longevity clinics serving local African populations remain a future thesis. The opportunity is real, but contingent on prerequisites that have not yet materialized. Investors should understand this distinction clearly: the India model that makes pure play clinics viable has specific structural conditions, and Egypt and Nigeria are developing toward those conditions rather than having arrived at them.

Egypt and Nigeria: The Scale Argument

Egypt with around 117 million people and Nigeria with 233 million represent the only African markets with demographic scale comparable (to some extent) to India’s logic. If around 20% percent penetration of health conscious consumer behavior is required for clinic network viability, these markets can support multiple operators once conditions mature. The arithmetic is straightforward applied in Nigeria’s population it would represents around 47 million potential customers. Even accounting for income stratification and the “divide stated interest by three” calibration that Sottas emphasizes, the addressable base in these markets could eventually support substantial clinic infrastructure.

Egypt holds a particular advantage in connectivity to capital and operational expertise. Cairo functions as a node in the Gulf commercial network, with strong UAE investment ties across real estate, hospitality, and healthcare. Aldar Properties, the leading Abu Dhabi real estate developer managing a $13 billion portfolio across retail, residential, commercial, logistics and hospitality segments, holds a majority stake in Egyptian real estate development company SODIC. Moreover, the positioning with longevity offering also contributes to increasing local awareness around the healthspan importance increase that is grounded in longstanding self-care tradition. Essentially, The Precision Health Group establishes clinical capability and brand awareness that could translate to local market focus as demographics evolve.

Nigeria presents a different profile. In Nigeria today, this thesis remains even farer compared to the Egypt counter part. The wellness tourism entry vector not yet materializing to the magnitude of the East African or MENA counterparts but the demographic scale is unmatched on the continent. Nigeria’s challenge is more fundamental: economic volatility, currency instability, and infrastructure gaps create near term barriers that Egypt does not face to the same degree. Nigeria is plausibly a 10 to 15 year thesis where Egypt might be a 5 to 10 year thesis, though both remain speculative without evidence of the prerequisites emerging.

Prerequisites Not Yet Met

Pure play longevity clinics decoupled from tourism require three conditions that do not yet exist at scale in either Egypt or Nigeria. First, a substantial middle class with disposable income must emerge. The health conscious consumer segment that drives longevity clinic demand in India requires discretionary spending capacity for optimization services that deliver benefits over years, not immediate relief from acute symptoms. This consumer is making a conscious investment in future health and support xLongevity subscriptions rather than treating present illness. That investment mindset requires financial security that remains limited in both markets.

Second, price democratization of therapies must occur. Current longevity clinic pricing reflects the economics of small scale, high touch operations serving wealthy clientele. Swiss ultra premium programs at CHF 48,000 or more serve a global elite. Even the emerging accessible premium tier at $5,000 to $15,000 remains far beyond the reach of middle class consumers in Egypt or Nigeria. Technology may eventually enable this compression through AI driven diagnostics, standardized protocols, and commoditized inputs, but the pathway is not yet clear.

Third, category awareness and education must develop. Healthspan as a concept remains poorly understood even in developed markets. The Hevolution Foundation surveys reveal low consumer understanding of what longevity medicine actually offers and no shared frameworks for evaluating clinic quality. Each operator entering a market must educate its own customers, creating high acquisition costs that compound the profitability challenge. In markets where the concept is even less established, this education burden is substantial.

The Hevolution survey data offers a telling contrast: 67 percent of African respondents expressed willingness to participate in healthspan research, compared to 41 percent of Europeans who declined participation. The appetite exists. The infrastructure to capture it does not.

What Would Change the Thesis

Pure play longevity clinics decoupled from tourism require three conditions that do not yet exist at scale in either Egypt or Nigeria.

The first is a substantial middle class with disposable income. The health conscious consumer segment that drives longevity clinic demand in India requires discretionary spending capacity for optimization services that deliver benefits over years, not immediate relief from acute symptoms. This consumer is making a conscious investment in future health and supporting xLongevity subscriptions rather than treating present illness. That investment mindset requires financial security that remains limited in both markets. GDP growth, rising formal employment, currency stability, and expanding consumer credit access would all contribute to the emergence of the target demographic. Nigeria’s economic trajectory is particularly volatile. Egypt has shown more stability but faces its own macroeconomic challenges. External investors should monitor World Bank and IMF economic projections, consumer spending data, and healthcare expenditure growth as signals.

The second is price democratization of therapies. Current longevity clinic pricing reflects the economics of small scale, high touch operations serving wealthy clientele. Swiss ultra premium programs at CHF 48,000 or more serve a global elite. Even the emerging accessible premium tier at $5,000 to $15,000 remains far beyond the reach of middle class consumers in Egypt or Nigeria. Technology driven cost reduction in diagnostics, therapy standardization, and supply chain optimization could change this. AI integration for personalized protocol generation, which the Hevolution report identifies as a potential $110 billion pharma value creation opportunity, could be particularly significant. Evidence that $2,000 to $5,000 treatments can deliver meaningful healthspan benefits opens the mass market possibility.

The third is category awareness and education. Healthspan as a concept remains poorly understood even in developed markets. The Hevolution Foundation surveys reveal low consumer understanding of what longevity medicine actually offers and no shared frameworks for evaluating clinic quality. Each operator entering a market must educate its own customers, creating high acquisition costs that compound the profitability challenge. In markets where the concept is even less established, this education burden is substantial. The Hevolution survey data offers a telling contrast: 67 percent of African respondents expressed willingness to participate in healthspan research, compared to 41 percent of Europeans who declined participation. The appetite exists. The infrastructure to capture it does not.

Two additional developments would accelerate the timeline. Regulatory framework development following the UAE model would signal market readiness and reduce operator uncertainty. An Egyptian government initiative to establish longevity medicine guidelines, license specialized centers, and create clear scope of practice definitions would be significant. Watch for health ministry announcements, pilot programs, or partnerships with Gulf regulatory bodies. A first mover clinic demonstrating local market viability would also shift the thesis from theoretical to proven. Precision Wellness in Egypt operates at the intersection of tourism and local markets. Tracking its customer mix, repeat visit rates, and expansion plans will reveal whether local demand can sustain operations beyond the tourist channel.

To Conclude …

The longevity fever has reached Africa. Whether it becomes an industry depends on who builds what, where, and how patiently they wait.

If you made it this far, thank you. This was a long one. I hope it was worth your time.

References

Industry Reports

Global Wellness Institute. (2025). Global Wellness Economy Monitor 2025.

Hevolution Foundation. (2024). The Global Healthspan Report: Second Edition.

Longevity.Technology. (2025). Global Longevity Clinic Survey.

Luxury Partners. (2025). The Longevity Lever: Closing the Wellness Gap in

McKinsey & Company. (2024). The $2 Trillion Global Wellness Market Gets a Millennial and Gen Z Glow Up. McKinsey Future of Wellness Survey.

HVS Middle East Africa. (2025). Why Wellness Resorts Offer Healthy Investment Opportunities. HVS.

East Africa Venture Capital Association. (2025). Betting on East Africa’s Tourism: A Private Equity Perspective. EAVCA.

Academic Papers

Martinovic, A., et al. (2024). The Longevity Pyramid: A Comprehensive Framework for Healthspan Interventions. Frontiers in Aging.

Gómez-Olivé, F.X., et al. (2023). Telomere Length and Aging in Rural South Africa: Findings from the HAALSI Study. Journals of Gerontology: Biological Sciences, 78(11).

López-Otín, C., et al. (2023). Hallmarks of Aging: An Expanding Universe. Cell, 186(2), 243–278.

News Articles

African Business. (2025, June). Morocco prepares for 2030 World Cup limelight. African Business.

Africa24 TV. (2025, September 11). Longevity lands in Europe; It has a South African twist to it. Africa24 TV.

BeautyMatter. (2024, June 6). The Business of Wellness and Tourism in Africa. BeautyMatter.

DeAngelis, A. (2025, December 3). Aging startup Retro Bio chases $5 billion valuation. STAT News.

Fierce Biotech. (2022, January 19). Altos bursts out of stealth with $3B, a dream team C suite and a wildly ambitious plan to reverse disease. Fierce Biotech.

Financial Fortune Media. (2025, October 8). Longevity Clinic lands in East Africa, but it has a Kenyan twist to it. Financial Fortune Media.

Hamzelou, J. (2025, April 18). Longevity clinics around the world are selling unproven treatments. MIT Technology Review.

Hamzelou, J. (2024, March 18). The quest to legitimize longevity medicine. MIT Technology Review.

Hotel Online. (2024). The Estate Hotels and Residences Heralds a New Era for Longevity Tourism. Hotel Online.

Life Lately. (2025, October 8). Kenya Launches First Longevity Clinic in East Africa. Life Lately.

Moroccan National Tourist Office. (2025). Morocco is the country of wellbeing par excellence. Moroccan National Tourist Office.

Preissler, Y. (2025, June 24). Integrating Fitness, Wellness and Longevity into Hotel Investments. CoStar News / ISHC Global Insights.

SwissInfo. (2025). Can Saudi Arabia’s billions unlock the secrets to a longer, healthier life? SwissInfo.

SwissInfo. (2024). Swiss longevity clinics: snake oil or the key to healthy ageing? SwissInfo.

Expert Interviews

Sottas, P.E. (2025). Interview with Pierre Edouard Sottas, CEO of xLongevity. Personal interview.

Company & Organization Sources

Afrolongevity. (2025). About Afrolongevity.

Better by MTA. (2025). Medical Tourism Destination: Morocco. Medical Tourism Association.

Precision Health Group. (2025). About Precision Health.

Precision Wellness Egypt. (2025). About Us.